NOTICE OF SPECIAL MEETING OF SHAREHOLDERS ~~IN LIEU OF AN~~
~~ANNUAL GENERAL MEETING OF SHAREHOLDERS~~

You are cordially invited to attend the special ~~meeting in lieu of the 2020 annual general~~ meeting (the “special meeting”) of shareholders of Longevity Acquisition Corporation (“Longevity,” “Company,” “we,” “us” or “our”) to be held at ~~10:~~11:00 a.m. Eastern Time on ~~May ,~~November 20, 2020 at the offices of Longevity’s counsel, ~~Ellenoff Grossman~~Hunter Taubman Fischer & ~~Schole LLP, 1345~~Li LLC, 800 Third Avenue, ~~of the Americas, 11th Floor,~~Suite 2800, New York, New York ~~10105.~~10022. Shareholders that wish to listen to the special meeting via teleconference, but will not be able to participate in the special meeting or vote, may use the following teleconference dial-in numbers:

The special meeting is being held for the sole purpose of considering and voting upon the following proposals:

Each of the Extension ~~Proposal, the Director~~ Proposal and the Adjournment Proposal is more fully described in the accompanying proxy statement.

As previously disclosed on Longevity’s Current Report on Form 8-K filed on October 22, 2020, on October 21, 2020, Longevity entered into an Agreement and Plan of Merger (the “Merger Agreement”) with 4D Pharma PLC (“4D Pharma”), a public limited company incorporated under the laws of England and Wales, and Dolphin Merger Sub Limited (“Merger Sub”), a British Virgin Islands company limited by shares and a wholly-owned subsidiary of 4D Pharma, providing for, among other things, and subject to the conditions therein, the combination of Longevity and 4D Pharma pursuant to the proposed merger of Longevity with and into Merger Sub with Merger Sub continuing as the surviving entity and wholly-owned subsidiary of 4D Pharma (the “Merger”).

The purpose of the Extension Proposal is to allow Longevity more time to complete anits initial business combination with 4D Pharma or another proposed business combination. Our Amended and Restated Memorandum and Articles of Association ~~provide~~provided that Longevity ~~has~~had until May 29, 2020 to complete a business combination. ~~While we are currently~~This date was extended to November 30, 2020 pursuant to a vote of the shareholders on May 22, 2020 (the “May Extension”). Following redemptions of 2,643,178 of the Ordinary Shares in ~~discussions~~connection with ~~respect to several business combination opportunities, our~~the May Extension, a total of approximately $14.4 million remained in the Trust Account. As of October 9, 2020, approximately $14.6 million remained in the Trust Account. Our board of directors (the “Board”) believes that there may not be sufficient time before ~~May 29,~~November 30, 2020 to complete ~~a business combination.~~the Merger. Accordingly, our Board believes that in order to be able to consummate anits initial business combination with 4D Pharma or another proposed business combination, we need to obtain the Extension. Therefore, our Board has determined that it is in the best interests of our shareholders to extend the date by which Longevity must consummate a business combination to the Extended Date in order to provide our shareholders with the opportunity to participate in this prospective transaction. In the event that Longevity enters into a definitive agreement for a business combination prior to the special meeting, Longevity will issue a press release and file a Current Report on Form 8-K with the Securities and Exchange Commission announcing the definitive agreement for the proposed business combination.

Holders (“public shareholders”) of Longevity’s ordinary shares (“public shares”) sold in its initial public offering (“IPO”) may elect to redeem their public shares for theirpro rata portion of the funds available in the trust account in connection with the Extension Proposal (the “Election”) regardless of how such public shareholders vote in regard to those amendments, or whether they were holders of Longevity ordinary shares on the record date or acquired such shares after such date. This right of redemption is provided for and is required by Longevity’s Amended and Restated Memorandum and Articles of Association and Longevity also believes that such redemption right protects Longevity’s public shareholders from having to sustain their investments for an unreasonably long period if Longevity fails to find a suitable acquisition in the timeframe initially contemplated by its Amended and Restated Memorandum and Articles of Association. If the Extension Proposal is approved by the requisite vote of shareholders (and not abandoned), the remaining holders of public shares will retain their right to redeem their public shares for theirpro rata portion of the funds available in the trust account upon consummation of a business combination.

To exercise your redemption rights, you must ~~check the box on the proxy card provided for that purpose, return the proxy card in accordance with the instructions provided and~~ tender your shares to the Company’s transfer agent at least two business days prior to the special meeting. You may tender your shares by either delivering your share certificates to the transfer agent or by delivering your shares electronically using The Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) system. If you hold your shares in street name, you will need to instruct your bank, broker or other nominee to withdraw the shares from your account in order to exercise your redemption rights.

As the date hereof, there are 2,626,822 ordinary shares issued and outstanding. The per-share pro rata portion of the trust account was approximately ~~$10.60~~$10.74 as of ~~February 29,~~October 9, 2020. The closing price of Longevity’s shares on ~~May ,~~October 23, 2020 was ~~$ .~~$10.80. Longevity cannot assure shareholders that they will be able to sell their shares of Longevity in the open market, even if the market price per share is higher than the redemption price stated above, as there may not be sufficient liquidity in its securities when shareholders wish to sell their shares.

If the Extension Proposal is not approved and we do not consummate a business combination by ~~May 29,~~November 30, 2020 in accordance with our Amended and Restated Memorandum and Articles of Association, or if the Extension Proposal is approved and we do not consummate a business combination by the Extended Date, we will cease all operations except for the purpose of winding up and as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the outstanding public shares with the aggregate amount then on deposit in the trust account.

The affirmative vote of the holders of at least 65% of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special meeting and which vote on the Extension Proposal will be required to approve the Extension Proposal. The affirmative vote of a majority of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special ~~meeting and which vote on the Director Proposal is required to elect each of the two nominees as Class I directors pursuant to the Director Proposal.~~meeting. The affirmative vote of a majority of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special meeting and which vote on the Adjournment Proposal will be required to approve the Adjournment Proposal.

Our Board has fixed the close of business on ~~April 29,~~October 9, 2020 as the date for determining Longevity shareholders entitled to receive notice of and vote at the special meeting and any adjournment thereof. Only holders of record of Longevity shares on that date are entitled to have their votes counted at the special meeting or any adjournment thereof.

After careful consideration of all relevant factors, our Board has determined that the Extension Proposal ~~the Director Proposal~~ and the Adjournment Proposal are fair to and in the best interests of Longevity and its shareholders, has declared them advisable and recommends that you vote or give instruction to vote “FOR” the Extension Proposal ~~“FOR” each director nominee~~ and “FOR” the Adjournment Proposal.

Enclosed is the proxy statement containing detailed information concerning the Extension ~~Proposal, the Director~~ Proposal and the Adjournment Proposal and the special meeting. Whether or not you plan to attend the special meeting, we urge you to read this material carefully and vote your shares.

Your vote is important. Please sign, date and return your proxy card as soon as possible to make sure that your shares are represented at the special meeting. If you are a shareholder of record, you may also cast your vote in person at the special meeting. If your shares are held in an account at a brokerage firm or bank, you must instruct your broker or bank how to vote your shares, or you may cast your vote in person at the special meeting by obtaining a proxy from your brokerage firm or bank.

Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Shareholders to be held on ~~May __,~~November 20, 2020: This notice of meeting, the accompanying proxy statement and our Annual Report on Form 10-K for the fiscal year ended February ~~28,~~29, 2020 are available at ~~________________.~~https://www.cstproxy.com/longevityacquisitioncorp/2020.

The special ~~meeting in lieu of the 2020 annual general~~ meeting (the “special meeting”) of shareholders of Longevity Acquisition Corporation (“Longevity,” “Company,” “we,” “us” or “our”), a British Virgin Islands business company, will be held at ~~10:~~11:00 a.m. Eastern Time on ~~May ,~~November 20, 2020, at the offices of ~~Longevity’s counsel, Ellenoff Grossman~~Hunter Taubman Fischer & ~~Schole LLP, 1345~~Li LLC, 800 Third Avenue, ~~of the Americas, 11~~^th ~~Floor,~~Suite 2800, New York, New York ~~10105.~~10022.

The special meeting is being held for the sole purpose of considering and voting upon the following proposals:

The Extension Proposal is essential to the overall implementation of the Board’s plan to extend the date by which Longevity must complete an initial business combination. The purpose of the Extension Proposal is to allow Longevity more time to complete anits initial business ~~combination. In the event that Longevity enters into a definitive agreement for a business~~ combination ~~prior to the special meeting, Longevity will issue a press release and file a Current Report on Form 8-K~~ with ~~the Securities and Exchange Commission announcing the definitive agreement for the~~4D Pharma or another proposed business combination.

If the Extension Proposal is approved, our sponsor, or its designees, has agreed to contribute to us as a loan (i) $0.025 for each public share that is not redeemed (the “Initial Contribution”) in connection with the special meeting plus (ii) $0.025 for each public share that is not redeemed in connection with the special meeting for each subsequent calendar month on the 30^thday of each subsequent month, or portion thereof, that is needed by Longevity to complete an initial business combination until the Extended Date (the “Additional Contributions” and, collectively with the Initial Contribution, the “Contributions”). For example, if Longevity takes until November 30, 2020 to complete its business combination, which would represent six calendar months, our sponsor or its designees would make aggregate maximum Contributions of approximately $600,000, or $0.15 per share (assuming no public shares were redeemed). Assuming the Extension Proposal is approved, the Initial Contribution will be deposited in the trust account promptly following the special meeting. Each Additional Contribution will be deposited in the trust account within thirty calendar days from the beginning of such calendar month (or portion thereof). Accordingly, if the Extension Proposal is approved and the Extension is implemented and the Company takes the full time through the Extended Date to complete the initial business combination, the redemption amount per share at the meeting for such business combination or the Company’s subsequent liquidation will be approximately $10.75 per share, in comparison to the current redemption amount of ~~$10.60~~$10.74 per share (as of ~~February 29,~~October 9, 2020 and assuming no public shares were redeemed). The Contributions are conditioned upon the implementation of the Extension Proposal. The Contributions will not occur if the Extension Proposal is not approved or the Extension is abandoned. The amount of the Contributions will not bear interest and will be repayable by us to our sponsor or its designees upon consummation of an initial business combination. If our sponsor or its designees advises us that it does not intend to make the Contributions, then the Extension Proposal ~~the Director Proposal~~ and the Adjournment Proposal will not be put before the shareholders at the special meeting and, unless we can complete an initial business combination by ~~May 29,~~November 30, 2020, we will dissolve and liquidate in accordance with the Amended and Restated Memorandum and Articles of Association. Our sponsor or its designees will have the sole discretion whether to continue extending for additional calendar months until the Extended Date and if our sponsor determines not to continue extending for additional calendar months, its obligation to make Additional Contributions will terminate.

Holders (“public shareholders”) of Longevity’s ordinary shares sold in its IPO (“public shares”) may elect to redeem their public shares for theirpro rata portion of the funds available in the trust account in connection with the Extension Proposal (the “Election”) regardless of how such public shareholder votes in regard to the Extension Proposal, or whether they were holders of Longevity ordinary shares on the record date or acquired such shares after such date. Longevity believes that such redemption right protects Longevity’s public shareholders from having to sustain their investments for an unreasonably long period if Longevity fails to find a suitable acquisition in the timeframe initially contemplated by its Amended and Restated Memorandum and Articles of Association. If the Extension Proposal is approved and implemented, the remaining public shareholders will retain their right to redeem their public shares for theirpro rata portion of the funds available in the trust account upon consummation of a business combination.

If the Extension Proposal is approved, such approval will constitute consent for the Company to (i) remove from the trust account an amount (the “Withdrawal Amount”) equal to the number of public shares properly redeemed in connection with the shareholder vote on the Extension Proposal multiplied by the per-share price equal to the aggregate amount then on deposit in the trust account as of two business days prior to the special meeting, including interest earned on the trust account deposits (which interest shall be net of taxes payable), divided by the number of then outstanding public shares and (ii) deliver to the holders of such redeemed public shares their portion of the Withdrawal Amount. The remainder of such funds shall remain in the trust account and be available for use by the Company to complete a business combination on or before the Extended Date. Holders of public shares who do not redeem their public shares now will retain their redemption rights and their ability to vote on a business combination through the Extended Date if the Extension Proposal is approved.

The removal of the Withdrawal Amount from the trust account in connection with the Election will reduce the amount held in the trust account following the redemption, and the amount remaining in the trust account may be significantly reduced from the approximately ~~$41.9~~$14.6 million that was in the trust account as of ~~November 30, 2019.~~October 9, 2020. In such event, Longevity may need to obtain additional funds to complete a business combination and there can be no assurance that such funds will be available on terms acceptable to the parties or at all.

If the Extension Proposal is not approved or we do not consummate a business combination by ~~May 29,~~November 30, 2020, as contemplated by our IPO prospectus and in accordance with our Amended and Restated Memorandum and Articles of Association, we will, as promptly as reasonably possible but not more than five business days thereafter, distribute the aggregate amount then on deposit in the trust account (net of taxes payable, and less up to $50,000 of interest to pay liquidation expenses), pro rata to our public shareholders by way of redemption and cease all operations except for the purposes of winding up of our affairs by way of a voluntary liquidation, as further described herein. Any redemption of public shareholders from the trust account shall be effected as required by our Amended and Restated Memorandum and Articles of Association prior to our commencing any voluntary liquidation. If we are required to liquidate prior to distributing the aggregate amount then on deposit in the trust account (net of taxes payable, and less up to $50,000 of interest to pay liquidation expenses) pro rata to our public shareholders, then such winding up, liquidation and distribution must comply with the applicable provisions of the BVI Business Companies, 2004 Act. In that case, investors may be forced to wait beyond ~~May 29,~~November 30, 2020 before the proceeds of our trust account become available to them, and they receive the return of their pro rata portion of the proceeds from our trust account. Except as otherwise described herein, we have no obligation to return funds to investors prior to the date of any redemption required as a result of our failure to consummate our initial business combination within the period described above or our liquidation, unless we consummate our initial business combination prior thereto and only then in cases where investors have sought to redeem their ordinary shares. Only upon any such redemption of public shares as we are required to effect or any liquidation will public shareholders be entitled to distributions if we are unable to complete our initial business combination.

The initial shareholders have waived their rights to participate in any liquidation distribution with respect to their founder shares. As a consequence of such waivers, a liquidating distribution will be made only with respect to the public shares. There will be no distribution from the trust account with respect to Longevity’s warrants or rights, which will expire worthless in the event we wind up.

You are also being asked to direct the chairman of the special meeting to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Extension ~~Proposal or the Director~~ Proposal.

The record date for the special meeting is ~~April 29,~~October 9, 2020. Record holders of Longevity ordinary shares at the close of business on the record date are entitled to vote or have their votes cast at the special meeting. On the record date, there were ~~5,270,000~~2,626,822 outstanding ordinary shares of Longevity, including ~~4,000,000~~1,356,822 outstanding public shares. Longevity’s warrants and rights do not have voting rights.

This proxy statement contains important information about the special meeting and the proposals. Please read it carefully and vote your shares.

This proxy statement is dated ,October 26, 2020 and is first being mailed to shareholders on or about that date.

These Questions and Answers are only summaries of the matters they discuss. They do not contain all of the information that may be important to you. You should read carefully the entire document, including the annexes to this proxy statement.

We believe that some of the information in this proxy statement constitutes forward-looking statements. You can identify these statements by forward-looking words such as “may,” “expect,” “anticipate,” “contemplate,” “believe,” “estimate,” “intends,” and “continue” or similar words. You should read statements that contain these words carefully because they:

• contain projections of future results of operations or financial condition; or

We believe it is important to communicate our expectations to our shareholders. However, there may be events in the future that we are not able to predict accurately or over which we have no control. The cautionary language discussed in this proxy statement provide examples of risks, uncertainties and events that may cause actual results to differ materially from the expectations described by us in such forward-looking statements, including, among other things, claims by third parties against the trust account, unanticipated delays in the distribution of the funds from the trust account and Longevity’s ability to finance and consummate any proposed business combination. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this proxy statement.

All forward-looking statements included herein attributable to Longevity or any person acting on Longevity’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except to the extent required by applicable laws and regulations, Longevity undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this proxy statement or to reflect the occurrence of unanticipated events.

We are a blank check company formed pursuant to the laws of the British Virgin Islands on March 9, 2018 for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, exchangeable share transaction or other similar business transaction with one or more operating businesses or assets. We are focusing our efforts on seeking and completing an initial business combination with a company that has an enterprise value of between $150 million and $250 million, although a target entity with a smaller or larger enterprise value may be considered.

On August 31, 2018, we consummated the IPO of 4,000,000 units at a price of $10.00 per unit, generating gross proceeds of $40,000,000. Simultaneously with the closing of the IPO, we consummated the sale of 270,000 private placement units to our sponsor and the underwriter of our IPO at a price of $10.00 per unit, generating gross proceeds of $2,700,000.

The units began trading on August 29, 2018 on the NASDAQ Capital Market under the symbol “LOAC.”

Commencing on October 15, 2018, the securities comprising the units began separately trading. The units, ordinary shares, rights and warrants are trading on the NASDAQ Stock Market under the symbols “LOACU,” “LOAC,” “LOACR” and “LOACW,” respectively. The aggregate market value of the ordinary shares outstanding, other than shares held by persons who may be deemed affiliates of the registrant, computed by reference to the closing sales price for the ordinary shares on ,October 23, 2020, as reported on the Nasdaq Capital Market, was approximately ~~$ .~~$10.80. 

Prior to our IPO, our sponsor purchased an aggregate of 1,150,000 ordinary shares initially purchased by our sponsor in a private placement prior to our IPO (“founder shares”) for an aggregate purchase price of $25,000. 150,000 founder shares were forfeited in October 2018 because the underwriters’ over-allotment option in connection with the Company’s initial public offering was not exercised.

The net proceeds of the IPO plus the proceeds of the sale of the private placement units were deposited in the trust account.

As of ~~November 30, 2019,~~October 9, 2020, the record date, we had approximately ~~$41.9~~$14.6 million in the trust account. As

The mailing address of ~~November 30,~~Longevity’s principal executive office is Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai, People’s Republic of China, and its telephone number is (86) 21-60832028.

On August 28, 2019, ~~$26,294~~we received a written notice (the “Notice”) from the Listing Qualifications Department of ~~cash~~The Nasdaq Stock Market (“Nasdaq”) indicating that we were not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which required us to have at least 300 public holders for continued listing on the NASDAQ Capital Market. The Notice was ~~held outside~~only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of our securities on the Nasdaq Capital Market.

The Notice states that we have 45 calendar days to submit a plan to regain compliance with the Minimum Public Holders Rule. We intend to submit a plan to regain compliance with the Minimum Public Holders Rule within the required timeframe. If Nasdaq accepts our plan, Nasdaq may grant us an extension of up to 180 calendar days from the date of the ~~trust account and is available for working capital purposes.~~Notice to evidence compliance with the Minimum Public Holders Rule. If Nasdaq does not accept our plan, we will have the opportunity to appeal the decision in front of a Nasdaq Hearings Panel.

On February 21, 2020, we issued an unsecured promissory note in the amount of $400,000, representing $0.10 per public share, to our sponsor. Our sponsor deposited such funds into our trust account. As a result, the period of time we have to consummate a business combination had been extended by three months to May 28, 2020. The note bears no interest and is repayable in full upon consummation of the Company’s initial business combination. Our sponsor had previously provided similar extension loans on two other occasions.

~~The mailing address~~On May 22, 2020, we held a special meeting (the “May Special Meeting”) of ~~Longevity’s principal executive office is Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai, People’s Republic~~shareholders in lieu of ~~China District, and its telephone number is (86) 21-60832028.~~

~~Longevity is currently in discussions~~the 2020 annual general meeting of shareholders. At the May Special Meeting, our shareholders approved the following items: (i) an amendment to ~~complete a business combination that will qualify as an initial business combination under its~~the Amended and Restated Memorandum and Articles of ~~Association. In~~Association to extend the ~~event that Longevity enters into a definitive agreement for~~date by which the Company must consummate a business combination (the “May Extension”) from May 29, 2020 to November 30, 2020 (such date or later date, as applicable, the “May Extended Date”) (the “May Extension Proposal”), and (ii) a proposal to elect each of Messrs. Jun Liu and Pai Liu as Class I directors of the Company with each such director to serve until the second annual general meeting of shareholders following the May Special Meeting or until his or her successor is elected and qualified (the “Director Proposal”). The affirmative vote of at least 65% of the Ordinary Shares of the Company entitled to vote which were present, in person or by proxy, at the May Special Meeting and which voted on the May Extension Proposal was required to approve the May Extension Proposal. The affirmative vote of a majority of the Company’s Ordinary Shares entitled to vote which were present (in person or by proxy) at the May Special Meeting and which vote on the Director Proposal is required to elect each of the two nominees pursuant to the Director Proposal.

In connection with the May Special Meeting, we also agreed that if the May Extension Proposal is approved, our sponsor, or its designees, has agreed to contribute to us as a loan (i) $0.025 for each public share that is not redeemed (the “May Initial Contribution”) in connection with the special meeting plus (ii) $0.025 for each public share that is not redeemed in connection with the May Special Meeting for each subsequent calendar month on the 30th day of each subsequent month, or portion thereof, that is needed by Longevity to complete an initial business combination until the May Extended Date (the “May Additional Contributions” and, collectively with the May Initial Contribution, the “May Contributions”). Given that the May Extension Proposal was approved, the May Initial Contribution would be deposited in the Trust Account promptly following the May Special Meeting. Each May Additional Contribution would be deposited in the Trust Account within thirty calendar days from the beginning of such calendar month (or portion thereof). The May Contributions were conditioned upon the implementation of the May Extension Proposal. The amount of the May Contributions do bear interest and would be repayable by us to our sponsor or its designees upon consummation of an initial business combination.

Following redemptions of 2,643,178 of the Ordinary Shares in connection with the May Extension, a total of approximately $14.4 million remained in the Trust Account. As of October 9, 2020, the record date, we had approximately $14.6 million in the trust account.

On October 21, 2020, Longevity entered into the Merger Agreement with 4D Pharma and Merger Sub.

Pursuant to the Merger Agreement, among other things, we will merge with and into Merger Sub, with Merger Sub continuing as the surviving entity and a wholly-owned subsidiary of 4D Pharma (the “Merger” and the “Surviving Company”). The Merger will become effective at such time on the closing date as the articles containing the plan of the merger and such other items (the “Articles of Merger”) and the resolution amending Merger Sub's memorandum or articles of association and their amendment are registered by the registrar of corporate affairs of the British Virgin Islands or at such other time subsequent thereto, but not exceeding 30 days from such registration, as mutually agreed between 4D Pharma and us and specified in the Articles of Merger (the “Effective Time”).

At the Effective Time, each of our ordinary shares (the “Company Shares”) issued and outstanding prior to the Effective Time (excluding shares held by 4D Pharma and us and dissenting shares, if any) will be automatically converted into the right to receive the Per Share Merger Consideration (as defined below), and each warrant to purchase our ordinary shares and right to receive our ordinary shares that is outstanding immediately prior to the Effective Time will be assumed by 4D Pharma and automatically converted into a warrant to purchase ordinary shares of 4D Pharma and a right to receive ordinary shares of 4D Pharma, payable in Parent ADSs (as defined below) (the “Parent Shares”), respectively.

Pursuant to the Merger Agreement, the merger consideration payable upon the Effective Time (the “Merger Consideration”) consists of the Per Share Merger Consideration (as defined below).

The “Per Share Merger Consideration” means the right to receive 7.5315 Parent Shares for each Company Share issued and outstanding immediately prior to the Effective Time.

4D Pharma shall (i) issue Parent Shares equal to the Per Share Merger Consideration multiplied by the number of Company Shares registered in the name of our shareholders (“Company Shareholders”) immediately prior to the Effective Time (the “Share Merger Consideration”) and (ii) issue to such Company Shareholders the number of American Depositary Shares of 4D Pharma (“Parent ADS”) equal to the Share Merger Consideration multiplied by the exchange rate ratio of 1 4D Pharma ADS for every 8 shares of Per Share Merger Consideration (the “Merger Consideration”).

4D Pharma is obligated to cause all rights to indemnification and advancement of expenses and all limitations on liability existing in favor of any employee, officer or director of us to survive the consummation of the transactions contemplated in the Merger Agreement and continue in full force and effect and be honored by the Surviving Company and 4D Pharma after the Effective Time.

Under the Merger Agreement, 4D Pharma and its subsidiaries, including the Merger Sub (collectively, the “Group Companies”), on the one hand, and we, on the other hand, each made representations and warranties to each other, including without limitation as to such parties’ corporate powers, capital structure, financial condition, legal activity and compliance, and in the case of each of the Group Companies, its assets, liabilities, properties, taxes, recent operations, contracts, related party transactions, insurance, employee matters and certain other matters.

The assertions embodied in those representations and warranties were made for purposes of the Merger Agreement and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating such agreement. The representations and warranties in the Merger Agreement are also modified in important part by the disclosure schedules and annexes attached thereto, which are not filed publicly and which may be subject to contractual standards of materiality or material adverse effect applicable to the contracting parties that differ from what may be viewed as material to investors. The representations and warranties in the Merger Agreement and the items listed in the disclosure schedules were used for the purpose of allocating risk among the parties rather than establishing matters as facts. We do not believe that the disclosure schedules contain information that is material to an investment decision. Investors are not third-party beneficiaries under the Merger Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the parties thereto or any of their respective subsidiaries or affiliates.

Each party agreed in the Merger Agreement to use their commercially reasonable efforts to effect the closing of the transaction contemplated thereby. The Merger Agreement also contains covenants of the parties during the period between the signing of the Merger Agreement and the earlier of the Effective Time or the termination of the Merger Agreement, including covenants regarding (1) the operation of their respective businesses in the ordinary course of business, (2) the provision of access to their books and records, (3) confidentiality, (4) exclusive dealing, (5) backstop arrangement, (6) notifications of certain breaches, consent requirements or other matters, (7) efforts to consummate the Merger and obtain third party and regulatory approvals, and (8) with respect to 4D Pharma, the establishment of an ADR facility.

We also agreed, as promptly as practicable after the date of the Merger Agreement, to file a proxy statement (the “Merger Proxy Statement”) for a special meeting ~~Longevity~~in lieu of an annual meeting of its shareholders to approve the Merger Agreement and related matters (the “Shareholder Meeting”) and provide all of its public shareholders with the opportunity to redeem their public shares in conjunction with the shareholder vote (the “Offer”) and 4D Pharma shall cause to be filed with the SEC a registration statement on Form F-4, in which the Merger Proxy Statement will ~~issue~~be included. Without limitation, in the Merger Proxy Statement, the Company must seek from its shareholders (i) approval of the Merger Agreement, (ii) approval that the Merger will constitute a ~~press release~~Business Combination, as defined by the Memorandum and ~~file~~Articles of Association of the Company, (iii) approval to obtain any and all other approvals necessary or advisable to effect the consummation of the Merger (the proposals set forth in the foregoing clauses (i) through (iii) are referred to as the “Company Proposals”), and (iv) any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the approval of the Company Proposals, on the date on which such meeting is held.

We agreed, through its board of directors, to recommend that the Company Shareholders vote in favor of all Company Proposals, and not withdraw or modify such recommendation prior to termination of the Merger Agreement.

From the date of execution of the Merger Agreement through the Closing, we shall use all reasonable efforts to remain as a public company on, and for its securities to be tradable over the Nasdaq Capital Market. 4D Pharma shall use all reasonable efforts to apply for a listing of Parent ADSs on, and for Parent ADSs to be tradable over, the Nasdaq Stock Market.

Consummation of the transactions contemplated by the Merger Agreement is subject to the satisfaction or waiver by the respective parties of a number of conditions, including the approval of the Merger Agreement and the transactions contemplated thereby by 4D Pharma’s and our respective shareholders. Other closing conditions include, among others: (i) the respective representations of the parties to each other being true and correct, except as would not have a material adverse effect; (ii) performance and compliance with in all material respects of the respective covenants and agreements of each party; (iii) the execution of the Backstop Agreements (as defined below); (iv) we having at least $11,750,000 of net tangible assets and at least $14,600,000 in cash, immediately prior to the Effective Time; (v) no material adverse effect with respect to 4D Pharma or us having occurred since the date of the Merger Agreement; and (vi) the approval for listing on Nasdaq (subject to official notice of issuance) of the Parent ADSs to be issued in connection with the Merger.

A copy of the Merger Agreement is filed with a Current Report on Form 8-K dated October 22, 2020 (the“Report”) as Exhibit 2.1 and is incorporated herein by reference. The foregoing description of the Merger Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the full text of the Merger Agreement.

This section describes the material provisions of certain additional agreements entered into or to be entered into pursuant to the Merger Agreement (the “Related Agreements”) but does not purport to describe all of the terms thereof. The following summary is qualified in its entirety by reference to the complete text of each of the Related Agreements, copies of each of which are attached hereto as exhibits. Shareholders and other interested parties are urged to read such Related Agreements in their entirety.

Concurrently with execution of the Merger Agreement, Whale Management Corporation (the “SPAC Sponsor”) entered into a voting and support agreement with 4D Pharma (the “Voting Agreement”). Under the Voting Agreement, the SPAC Sponsor thereto generally agreed to vote all of its capital shares in Longevity in favor of the Merger Agreement and the transactions contemplated thereby, each other Company Proposal and any other proposal included in the Proxy Statement related to the Merger for which our board of directors has recommended that the Company Shareholders vote in favor and against any competing transaction. The Voting Agreement prevents transfers of the Longevity shares held by the SPAC Sponsor between the date of the Voting Agreement and the termination of the Voting Agreement, subject to certain limited exceptions.

The Voting Agreement will terminate upon the earliest of (a) the mutual written consent of us and the SPAC Sponsor, (b) the termination of the Merger Agreement and (c) the Effective Time.

A copy of the Voting Agreement is filed with the ~~SEC announcing~~Report as Exhibit 10.1 and is incorporated herein by reference. The foregoing description of the ~~definitive agreement for~~Voting Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the ~~proposed business combination.~~full text of the Voting Agreement.

The Merger Agreement contemplates that, at the Effective Time, 4D Pharma will enter into a lock-up agreement with the SPAC Sponsor and certain shareholders of 4D Pharma immediately prior to the Effective Time, in substantially the form attached to the Merger Agreement (each, a “Lock-Up Agreement”), with respect to the Merger Consideration received in the Merger (collectively, the “Restricted Securities”). In such Lock-Up Agreement, each holder will agree that, subject to certain exceptions, during the period ending twelve months after the Effective Time, it will not (i) lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Restricted Securities, (ii) enter into any swap, short sale, hedge or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii) publicly disclose the intention to effect any transaction specified in clause (i) or (ii), or (iv) make any demand for or exercise any right with respect to the registration of any shares of the our common stock.

The agreed form of the Lock-Up Agreement is filed with the Report as Exhibit 10.2 and is incorporated herein by reference. The foregoing description of the Lock-Up Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the full text of the Lock-Up Agreement.

Concurrently with execution of the Merger Agreement, we entered into certain Backstop Agreements (the “Backstop Agreement”) with 4D Pharma, SPAC Sponsor and certain investors (the “Buyers”). Under the Backstop Agreements, the Buyers have committed to provide financial backing to the Company immediately prior to the Effective Time, in the event of redemptions by Company shareholders, in the aggregate amount of up to $14,600,000 (the “Backstop Amount”).

Under the Backstop Agreement, (i) we and SPAC Sponsor, (ii) 4D Pharma, and (iii) the Buyers each made representations and warranties to each other, including but not limited to each parties’ organization, authority and non-contravention, with respect to 4D Pharma, the valid issuance of shares, and with respect to the Buyers, the sophistication of the Buyers and their compliance with applicable securities laws.

The Backstop Agreement also provides that 4D Pharma shall within thirty (30) days after the Effective Time, file a registration statement under the Securities Act registering the resale of the ordinary shares issued by 4D Pharma pursuant to the Merger.

The form of the Backstop Agreement is filed with this Report as Exhibit 10.3 and is incorporated herein by reference. The foregoing description of the Backstop Agreement does not purport to be complete and is subject to, and is qualified in its entirety by, the full text of the Backstop Agreement.

On October 22, 2020, we, upon receipt of the principal, issued an unsecured promissory note in the aggregate principal amount of $1,860,000 (the “Note”) to certain investors, their registered assignees or successors in interest (the “Payees”). The Note was issued in connection with the Merger Agreement.

The Note is non-interest bearing and is payable on the earliest to occur of (i) immediately following the date on which the Company consummates its initial business and (ii) the date that the winding up of the Company is effective (such date, the “Maturity Date”). The principal balance may be prepaid at any time without penalty.

All amounts owed by us under the Note become immediately due and payable upon an event of default, which includes our failure to pay the principal amount due within 5 business days of the Maturity Date and the Company’s voluntary or involuntary bankruptcy. Pursuant to the Note, the Payees waived all rights, title, interest or claim in, or to, any distribution of, or from, the trust account in which the proceeds from our initial public offering (“IPO”).

The foregoing is a brief description of the material terms and conditions of the Note, a copy of which is attached as Exhibit 10.4 to the Report and incorporated herein by reference.

Concurrent with the execution of the Merger Agreement and the receipt of the proceeds from the Note, Messrs. Matthew Chen, Teddy Zheng, Yukman Lau and Pai Liu resigned from their positions of Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”), director of the Board, and director of the Board, respectively (collectively, the “Resignations”). The Resignations were not as a result of any disagreement with the Company relating to its operations, policies or practices.

On the same date, the Board appointed Alex Lyamport as CEO and director of the Board, Matthew Chen as CFO, Nicholas H. Adler as director of the Board and chairman of the compensation committee of the Board, and Jerry L. Hutter as director of the Board and chairman of the audit committee of the Board, to fill in the vacancies created by the Resignations. Our Board currently consists of two existing directors of the Board, Messrs. Matthew Chen and Jun Liu, and three newly appointed directors, Messrs. Alex Lyamport, Nicholas H. Adler and Jerry L. Hutter.

The biographies of the newly appointed CEO and directors of the Board are set forth below.

Mr. Lyamport, age 49, has over 20 years of experience in origination, structuring and closing deals in media, technology, energy, consumer goods and agriculture in Central and Eastern Europe. He also has a significant understanding of East-West capital markets and cross-border M&A. He has been a Director and CFO of Navigation Acquisition Corp. (TSXV: NAQ) since January 2018 and a Director at Navigator Principal Investors, LLC since 2012. From 2012 to 2014, Mr. Lyamport was CIS Acquisition Ltd.’s regional mergers and acquisitions consultant when the company raised US$40,000,000 from US institutional and retail investors pursuant to its initial public offering. While working for CIS Acquisition, he provided advice and assistance in connection with the identification of target businesses and completion of the company’s business acquisition. From 2003 to 2012, he was the cofounder and Head of Capital Markets of Link Capital, an Eastern European financial advisory firm. From 2005 to 2009, Alex was the cofounder and director of iMusic TV GmbH, Germany’s second largest music television channel and multimedia group. He played active role in strategy and fundraising. Mr. Lyamport attended CUNY, Brooklyn College and his area of study was Adapted Physical Education.

Nicholas H. Adler, age 45, is a practicing attorney in Nashville, Tennessee specializing in defense litigation, bankruptcy, foreclosure, and real estate matters. Mr. Adler is admitted to practice law in New York and Tennessee as well as all Federal districts within Tennessee. He received his B.A. in political science from Vanderbilt University and his J.D. from The Washington and Lee University School of Law. After his graduation from law school in 2001, Mr. Adler practiced with a large international firm in New York specializing in securities regulation. Since 2005, his practice has focused on the representation of national and regional credit grantors in Tennessee. He is also active in real estate development and asset management in Nashville.

Mr. Hutter, age 77, has over forty years of experience as an auditor, controller, CFO and management consultant for firms ranging from Fortune 500 companies to smaller private sector corporations and not-for-profit organizations. Since 2010, Mr. Hutter has served as director and Audit Committee Chairman of DJSP Enterprises, Inc., which used to be traded on NASDAQ under the symbol of DJSP and is designated as an Audit Committee Financial Expert for SEC purposes. In 2003, he co-founded CFO Strategies, Inc., from which he later retired as the Chief Executive Officer in 2009. From 2001 to 2005, Mr. Hutter was employed by CBIZ MHM, LLC as a Senior Manager. In the past twelve years, Mr. Hutter has worked with numerous public companies as an advisor to the board of directors and the audit committee regarding issues of risk assessment, compliance and financial statement disclosures, including Maxwell Technologies, Inc. NetREIT, Youbet.com and A-Power Energy Generation, Ltd. Mr. Hutter is a former certified public accountant with Price Waterhouse Coopers, where he was certified with both the American Institute of Certified Public Accountants (AICPA) and the California Society of Certified Public Accountants. He holds a Bachelor of Science degree in Accounting from California State University at Long Beach, with special studies at the University of California at Los Angeles and San Diego State University.

You are not being asked to vote on a business combination at this time. If the Extension is implemented and you do not elect to redeem your public shares, you will retain the right to vote on any proposed business combination if and when it is submitted to shareholders and the right to redeem your public shares for apro rata portion of the trust account in the event such business combination is approved and completed or the Company has not consummated a business combination by the Extended Date.

On October 21, 2020, Longevity entered into the Merger Agreement with 4D Pharma and Merger Sub, providing for, among other things, and subject to the conditions therein, the combination of Longevity and 4D Pharma pursuant to the proposed merger of Longevity with and into Merger Sub with Merger Sub continuing as the surviving entity and wholly-owned subsidiary of 4D Pharma.

You are NOT being asked to vote on the proposed business combination with 4D Pharma at this time. If you are a public shareholder, you will have the right to vote on the proposed business combination with 4D Pharma when it is submitted to shareholders.

Longevity is proposing to amend its Amended and Restated Memorandum and Articles of Association to extend the date by which Longevity must consummate a business combination from November 30, 2020 to May 29, ~~2020 to November 30, 2020.~~2021, or such earlier date as determined by the Board.

The Extension Proposal is essential to the overall implementation of the Board’s plan to allow Longevity more time to complete a business combination. Approval of the Extension Proposal is a condition to the implementation of the Extension.

If the Extension Proposal is not approved and we have not consummated a business combination by ~~May 29,~~November 30, 2020, or if the Extension Proposal is approved and we have not consummated a business combination by the Extended Date, we will (a) cease all operations except for the purpose of winding up, (b) as promptly as reasonably possible but no more than five (5) Business Days thereafter, subject to lawfully available funds therefor, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the amount then on deposit in the trust account, including interest earned thereon not previously released to us for the payment of taxes (less up to $50,000 of interest to pay liquidation expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (c) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and the Board, dissolve and liquidate, subject (in the case of (b) and (c) above) to our obligations to provide for claims of creditors and the requirements of other applicable law. There will be no distribution from the trust account with respect to our warrants, which will expire worthless in the event we wind up.

A copy of the proposed amendment to the Amended and Restated Memorandum and Articles of Association of Longevity is attached to this proxy statement asAnnex A.

The Company’s IPO prospectus and Amended and Restated Memorandum and Articles of Association provide that the Company has until May 29, 2020 to effect a business combination under its terms. ~~While~~This date was extended to November 30, 2020 pursuant to a vote of the shareholders on May 22, 2020 (the “May Extension”). Following redemptions of 2,643,178 of the Ordinary Shares in connection with the May Extension, a total of approximately $14.4 million remained in the Trust Account after the May Extension. As of October 9, 2020, the record date, we ~~are currently~~had approximately $14.6 million in ~~discussions regarding~~the trust account. The purpose of the Extension Proposal is to allow Longevity more time to complete its initial business combination ~~opportunities,~~with 4D Pharma or another proposed business combination. Our Board believes therefore that it is in the best interests of the shareholders to continue our ~~Board currently believes that there will not be sufficient~~existence until the Extended Date in order to allow us more time ~~before May 29, 2020~~ to complete aour initial business combination. The Company’s IPO prospectus and Amended and Restated Memorandum and Articles of Association provide that the affirmative vote of the holders of at least sixty-five percent (65%) of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special meeting and which vote on the Extension Proposal is required to extend our corporate existence, except in connection with, and effective upon, consummation of a business combination. Additionally, our IPO prospectus and Amended and Restated Memorandum and Articles of Association provide for all public shareholders to have an opportunity to redeem their public shares in the case our corporate existence is extended as described above. Because we continue to believe that a business combination would be in the best interests of our shareholders, and because we will not be able to conclude a business combination within the permitted time period, the Board has determined to seek shareholder approval to extend the date by which we must complete a business combination beyond ~~May 29,~~November 30, 2020 to the Extended Date. We intend to hold another shareholder meeting prior to the Extended Date in order to seek shareholder approval of a proposed business combination.

We believe that the foregoing Amended and Restated Memorandum and Articles of Association provision was included to protect Company public shareholders from having to sustain their investments for an unreasonably long period if the Company failed to find a suitable business combination in the timeframe contemplated by the Amended and Restated Memorandum and Articles of Association. We also believe, however, that given the Company’s expenditure of time, effort and money on finding a business combination thus far, circumstances warrant providing public shareholders an opportunity to consider a business combination.

The holders of the founder shares have waived their rights to participate in any liquidation distribution with respect to such founder shares. There will be no distribution from the trust account with respect to Longevity’s warrants and rights, which will expire worthless in the event we wind up.

If the Extension Proposal is approved, Longevity will file an amended and restated Memorandum and Articles of Association with the Registrar of Corporate Affairs in the British Virgin Islands, incorporating the amendment set forth inAnnex A hereto. Longevity will remain a reporting company under the Securities Exchange Act of 1934 and its units, outstanding shares, rights and warrants will remain publicly traded. Longevity will then continue to work to execute a definitive agreement for a business combination and complete such a business combination by the Extended Date.

If the Extension Proposal is approved, but Longevity does not consummate a business combination by the Extended Date, we will (a) cease all operations except for the purpose of winding up, (b) as promptly as reasonably possible but no more than five (5) Business Days thereafter, subject to lawfully available funds therefor, redeem the outstanding public shares, at a per-share price, payable in cash, equal to the amount then on deposit in the trust account, including interest earned thereon not previously released to us for the payment of taxes (less up to $50,000 of interest to pay liquidation expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (c) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and the Board, dissolve and liquidate, subject (in the case of (b) and (c) above) to our obligations to provide for claims of creditors and the requirements of other applicable law. There will be no distribution from the trust account with respect to our rights or warrants which will expire worthless in the event we wind up.

Approval of the Extension Proposal will constitute consent for the Company to (i) remove from the trust account the Withdrawal Amount and (ii) deliver to the holders of such redeemed public shares their portion of the Withdrawal Amount. The remainder of such funds shall remain in the trust account and be available for use by the Company to complete a business combination on or before the Extended Date. Holders of public shares who do not redeem their public shares now will retain their redemption rights and their ability to vote on a business combination through the Extended Date if the Extension Proposal is approved.

You are not being asked to vote on a business combination at this time. If the Extension is implemented and you do not elect to redeem your public shares, you will retain the right to vote on any proposed business combination when it is submitted to shareholders and the right to redeem your public shares for apro rataportion of the trust account in the event such business combination is approved and completed or the Company has not consummated a business combination by the Extended Date.

If the Extension Proposal is approved, and the Extension is implemented, the removal of the Withdrawal Amount from the trust account will reduce the amount held in the trust account and Longevity’s net asset value based on the number of shares that seek redemption. Longevity cannot predict the amount that will remain in the trust account if the Extension Proposal is approved, and the amount remaining in the trust account may be only a small fraction of the approximately ~~$41.9~~$14.6 million that was in the trust account as of ~~November 30, 2019.~~October 9, 2020, the record date. However, we will not proceed if we do not have at least $5,000,001 of net tangible assets following approval of the Extension Proposal and the Election (not including the Contribution).

If the Extension Proposal is approved, the Company will provide the public shareholders making the Election, the opportunity to receive, at the time the Extension Proposal becomes effective, and in exchange for the surrender of their shares, apro rata portion of the funds available in the trust account, less any income taxes owed on such funds but not yet paid. Longevity has provided that all holders of public shares, whether they vote for or against the Extension Proposal, or whether they were holders of Longevity ordinary shares on the record date or acquired such shares after such date, may elect to redeem their public shares into their pro rata portion of the trust account and should receive the funds shortly after the special meeting. You will also be able to redeem your public shares in connection with any shareholder vote to approve a proposed business combination, or if the Company has not consummated a business combination by the Extended Date.

TO DEMAND REDEMPTION, YOU MUST ~~CHECK THE BOX ON THE PROXY CARD PROVIDED FOR THAT PURPOSE AND RETURN THE PROXY CARD IN ACCORDANCE WITH THE INSTRUCTIONS PROVIDED, AND, AT THE SAME TIME,~~ ENSURE YOUR BANK OR BROKER COMPLIES WITH THE REQUIREMENTS IDENTIFIED ELSEWHERE HEREIN, INCLUDING DELIVERING YOUR SHARES TO THE TRANSFER AGENT PRIOR TO THE VOTE ON THE EXTENSION PROPOSAL. You will only be entitled to receive cash in connection with a redemption of these shares if you continue to hold them until the effective date of the Extension Proposal.

In connection with tendering your shares for redemption, you must elect either to physically tender your share certificates to Continental Stock Transfer & Trust Company, the Company’s transfer agent, at Continental Stock Transfer & Trust Company, One State Street Plaza, 30th Floor, New York, New York 10004-1561, Attn: Mark Zimkind, mzimkind@continentalstock.com, prior to the vote for the Extension Proposal or to deliver your shares to the transfer agent electronically using The Depository Trust Company’s DWAC (Deposit/ Withdrawal At Custodian) System, which election would likely be determined based on the manner in which you hold your shares. The requirement for physical or electronic delivery prior to the vote at the special meeting ensures that a redeeming holder’s election is irrevocable once the Extension Proposal are approved. In furtherance of such irrevocable election, shareholders making the Election will not be able to tender their shares after the vote at the special meeting.

Through the DWAC system, this electronic delivery process can be accomplished by the shareholder, whether or not it is a record holder or its shares are held in “street name,” by contacting the transfer agent or its broker and requesting delivery of its shares through the DWAC system. Delivering shares physically may take significantly longer. In order to obtain a physical share certificate, a shareholder’s broker and/or clearing broker, DTC, and the Company’s transfer agent will need to act together to facilitate this request. There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC system. The transfer agent will typically charge the tendering broker $45 and the broker would determine whether or not to pass this cost on to the redeeming holder. It is the Company’s understanding that shareholders should generally allot at least two weeks to obtain physical certificates from the transfer agent. The Company does not have any control over this process or over the brokers or DTC, and it may take longer than two weeks to obtain a physical share certificate. Such shareholders will have less time to make their investment decision than those shareholders that deliver their shares through the DWAC system. Shareholders who request physical share certificates and wish to redeem may be unable to meet the deadline for tendering their shares before exercising their redemption rights and thus will be unable to redeem their shares.

Certificates that have not been tendered in accordance with these procedures prior to the vote for the Extension Proposal will not be redeemed for a pro rata portion of the funds held in the trust account. In the event that a public shareholder tenders its shares and decides prior to the vote at the special meeting that it does not want to redeem its shares, the shareholder may withdraw the tender. If you delivered your shares for redemption to our transfer agent and decide prior to the vote at the special meeting not to redeem your shares, you may request that our transfer agent return the shares (physically or electronically). You may make such request by contacting our transfer agent at the address listed above. In the event that a public shareholder tenders shares and the Extension Proposal is not approved or are abandoned, these shares will not be redeemed and the physical certificates representing these shares will be returned to the shareholder promptly following the determination that the Extension Proposal will not be approved or will be abandoned. The Company anticipates that a public shareholder who tenders shares for redemption in connection with the vote to approve the Extension Proposal would receive payment of the redemption price for such shares soon after the completion of the Extension Proposal. The transfer agent will hold the certificates of public shareholders that make the election until such shares are redeemed for cash or returned to such shareholders.

If properly demanded, the Company will redeem each public share for apro rata portion of the funds available in the trust account, less any income taxes owed on such funds but not yet paid, calculated as of two days prior to the special meeting. As of ~~February 29,~~October 9, 2020, this would have amounted to approximately ~~$10.60~~$10.74 per share. The closing price of Longevity’s shares on ,October 23, 2020 was $ . Accordingly, if the market price were to remain the same until the date of the special meeting, exercising redemption rights would result in a public shareholder receiving $ less for each share than if such shareholder sold the shares in the open market.$10.80.

If you exercise your redemption rights, you will be exchanging your public shares for cash and will no longer own the shares. You will be entitled to receive cash for these shares only if you properly demand redemption and tender your share certificate(s) to the Company’s transfer agent at least two business days prior to the special meeting. If the Extension Proposal is not approved or if they are abandoned, these shares will be returned promptly following the special meeting as described above.

If the Extension Proposal is approved by the requisite vote of shareholders, after the Withdrawal Amount has been removed from the trust account, the remaining holders of public shares will retain their right to redeem their shares for a pro rata portion of the funds available in the trust account upon consummation of its initial business combination. In addition, public shareholders who vote for the Extension Proposal and do not elect to exercise their redemption rights will have the opportunity to participate in any liquidation distribution if the Company has not completed a business combination by the Extended Date. However, the Company will not proceed with the Extension Proposal, if after the Election, the Company fails to have net tangible assets greater than $5,000,001.

As discussed above, after careful consideration of all relevant factors, our Board has determined that the Extension Proposal is fair to, and in the best interests of, Longevity and its shareholders. The Board has approved and declared advisable adoption of the Extension Proposal and recommends that you vote “FOR” such adoption. The Board expresses no opinion as to whether you should redeem your public shares.

When you consider the recommendation of our Board, you should keep in mind that our sponsor, executive officers and members of our Board have interests that may be different from, or in addition to, your interests as a shareholder. These interests include, among other things:

Approval of the Extension Proposal requires the affirmative vote of holders of at least 65% of the Company’s ordinary shares entitled to vote and which are present (in person or by proxy) at the special meeting and which voted on the Extension Proposal. Abstentions, which are not votes cast, will have no effect with respect to approval of this proposal.

All of Longevity’s directors, executive officers and their affiliates are expected to vote any shares owned by them in favor of the Extension Proposal. On the record date, directors and executive officers of Longevity and their affiliates beneficially owned and were entitled to vote 1,250,000 ordinary shares of Longevity representing approximately ~~23.7%~~47.6% of Longevity’s issued and outstanding ordinary shares.

In addition, Longevity’s directors, executive officers and their affiliates may choose to buy units or ordinary shares of Longevity in the open market and/or through negotiated private purchases. In the event that purchases do occur, the purchasers may seek to purchase shares from shareholders who would otherwise have voted against the Extension Proposal and elected to redeem their shares for a portion of the trust account. Any shares of Longevity held by affiliates will be voted in favor of the Extension Proposal. As this proposal is not a “routine” matter, brokers will not be permitted to exercise discretionary voting on this proposal.

The Board recommends that you vote “FOR” the Extension Proposal. The Board expresses no opinion as to whether you should redeem your public shares.

~~THE DIRECTOR PROPOSAL~~

~~At the special meeting, shareholders are being asked to elect two directors to the Board to each serve as Class I directors of the Company.~~

In connection with our IPO, the Board was divided into two Classes: the Class I directors and the Class II directors. The original Class I directors stand elected for a term expiring at the first annual general meeting and the original Class II directors stand elected for a term expiring at the Company’s second annual general meeting. Commencing at the first annual general meeting, and then at each following annual general meeting, directors elected to succeed those directors whose terms expire are elected for a term of office to expire at the second annual general meeting following their election. Directors whose terms expire at an annual general meeting may also be elected for a further two-year period, if nominated by the Board.

As the special meeting is in lieu of the Company’s 2020 annual general meeting (being the Company’s first annual general meeting since its IPO), the terms of the current Class I directors, Messrs. Jun Liu and Pai Liu, will expire at the special meeting. The Board has nominated Messrs. Jun Liu and Pai Liu, each a current director, for election as Class I directors, to hold office until the next annual general meeting of shareholders following this special meeting, or until his successor is elected and qualified.

Unless you indicate otherwise, shares represented by executed proxies in the form enclosed will be voted to elect each of Messrs. Jun Liu and Pai Liu unless one is unavailable, in which case such shares will be voted for a substitute nominee designated by the Board. We have no reason to believe that either nominee will be unavailable or, if elected, will decline to serve.

~~For a biography of Messrs. Jun Liu and Pai Liu, please see the section entitled “~~~~Management.~~”

Approval of each director requires the affirmative vote of holders of at least a majority of Longevity’s ordinary shares present (in person or by proxy) at the special meeting and voting on the Director Proposal. You may vote for, or withhold your vote from, both, or either, of the nominees. Abstentions, which are not votes cast, will have no effect with respect to approval of this proposal. As this proposal is not a “routine” matter, brokers will not be permitted to exercise discretionary voting on this proposal.

All of Longevity’s directors, executive officers and their affiliates are expected to vote any shares owned by them in favor of each nominee for Class I director. On the record date, directors and executive officers of Longevity and their affiliates beneficially owned and were entitled to vote 1,250,000 shares of Longevity representing approximately 23.7% of Longevity’s issued and outstanding shares.

~~The Board recommends that you vote “FOR” the election of the nominees named above.~~

The adjournment proposal, if adopted, will request the chairman of the special meeting (who has agreed to act accordingly) to adjourn the special meeting to a later date or dates to permit further solicitation of proxies. The adjournment proposal will only be presented to our shareholders in the event, based on the tabulated votes, there are not sufficient votes at the time of the special meeting to approve the Extension Proposal. If the adjournment proposal is not approved by our shareholders, it is agreed that the chairman of the meeting shall not adjourn the special meeting to a later date in the event, based on the tabulated votes, there are not sufficient votes at the time of the special meeting to approve the Extension Proposal.

The affirmative vote of a majority of the Company’s shares present (in person or by proxy) and voting on the Adjournment Proposal at the special meeting will be required to direct the chairman of the special meeting to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Extension Proposal. Abstentions will have no effect with respect to approval of this proposal. As this proposal is not a “routine” matter, brokers will not be permitted to exercise discretionary voting on this proposal.

THE SPECIAL MEETING

Date, Time and Place. The special meeting of Longevity’s shareholders will be held at ~~10:~~11:00 a.m., Eastern Time on ,November 20, 2020, at the offices of Longevity’s counsel, ~~Ellenoff Grossman~~Hunter Taubman Fischer & ~~Schole LLP,~~Li LLC, at ~~1345~~800 Third Avenue, ~~of the Americas, 11th Floor,~~Suite 2800, New York, NY ~~10105.~~10022.

Voting Power; Record Date. You will be entitled to vote or direct votes to be cast at the special meeting, if you owned Longevity ordinary shares at the close of business on ,October 9, 2020, the record date for the special meeting. You will have one vote per proposal for each Longevity share you owned at that time. Longevity rights and warrants do not carry voting rights.

Votes Required. The affirmative vote of the holders of at least 65% of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special meeting and which vote on the Extension Proposal will be required to approve the Extension Proposal. The affirmative vote of a majority of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the meeting and are voted is required to elect each of the two nominees as directors pursuant to the Director Proposal. The affirmative vote of a majority of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special meeting and are voted will be required to approve the Adjournment Proposal. Abstentions, which are not votes cast, will have no effect with respect to approval of these proposals. As these proposals are not “routine” matters, brokers will not be permitted to exercise discretionary voting on these proposals.

At the close of business on the record date, there were ~~5,270,000~~2,626,822 outstanding ordinary shares of Longevity each of which entitles its holder to cast one vote per proposal.

If you do not want the Extension Proposal approved, you should vote against the proposal. If you want to obtain your pro rata portion of the trust account in the event the Extension is implemented, which will be paid shortly after the shareholder meeting which is scheduled for ,November 20, 2020, you must vote for or against the Extension Proposal and demand redemption of your shares.

Proxies; Board Solicitation. Your proxy is being solicited by the Board on the proposal to approve the Extension ~~Proposal and the Director~~ Proposal being presented to shareholders at the special meeting. No recommendation is being made as to whether you should elect to redeem your shares. Proxies may be solicited in person or by telephone. If you grant a proxy, you may still revoke your proxy and vote your shares ~~in person~~ at the special meeting.

We have retained Advantage Proxy, Inc. (“Advantage Proxy”) to assist us in soliciting proxies. If you have questions about how to vote or direct a vote in respect of your shares, you may contact Advantage Proxy at (877) 870-8565 (toll free) or by email at ksmith@advantageproxy.com. The Company has agreed to pay Advantage Proxy a fee of $6,500 and expenses, for its services in connection with the special meeting.

~~MANAGEMENT~~

~~Directors and Executive Officers~~

~~Our directors and officers are as follows:~~

~~Name~~	23		~~Age~~		~~Position~~
~~Matthew Chen (1)~~		47		~~Chairman and Chief Executive Officer~~
~~Teddy Zheng~~		36		~~Chief Financial Officer~~
~~Yukman Lau (1)~~		65		~~Director~~
~~Jun Liu (2)~~		48		~~Director~~
~~Pai Liu (2)~~		34		~~Director~~

~~(1) Serves as a Class II Director.~~

~~(2) Serves as a Class I Director.~~

~~Matthew Chen~~ has served as our Chairman and Chief Executive Officer since June 2018. Since January 2018, Mr. Chen has served as Vice President of XiaoMingTaiJi Anime Limited Co., where Mr. Chen is mainly responsible for equity investment, acquisitions and corporate financing. From 2011 to January 2018, Mr. Chen served as the global head of the credit derivative market making platform at JP Morgan’s London branch. From 2008 to 2011, Mr. Chen served as the Asia credit derivative risk analysis manager at JP Morgan’s Hong Kong branch. From 2005 to 2008, Mr. Chen served as Managing Director at Bear Stearns, responsible for the firm’s equity derivative strategic product development. From 2003 to 2005, Mr. Chen served as Vice President at Realty Data Corp. an independent mortgage data provider. From 1998 to 2003, Mr. Chen served as Senior Manager at Imagine Software, a quantitative financial model provider. Mr. Chen holds a BS from Florida State University and MS Degree of Computer Science from New York University. We believe Mr. Chen is qualified to serve as a director because of his extensive financial and operations experience and the extensive network he has established throughout his career.

~~Teddy Zheng~~ has served as our Chief Financial Officer since July 2018. Mr. Zheng has served as executive director of Cyngus Equity, an investment and financial advisory firm in China, since October 2015. From April 2014 to October 2015, Mr. Zheng worked in the investment banking division of Lazard in China. From November 2010 to March 2014, Mr. Zheng worked in the investment banking division of JPMorgan First Capital in China. From June 2009 to October 2010, Mr. Zheng worked in the M&A and corporate finance division of UBS Investment Bank in China. Mr. Zheng received a bachelor degree in management information systems from Beijing Information Technology Institute and a master degree in management science and engineering from the School of Economics and Management of Tsinghua University.

~~Yukman Lau~~ has served as a member of our board of directors since January 2020. Ms. Lau has served as a partner of Guoxing Asset Co., Ltd., an investment company in China, since June 2016. From June 2006 to June 2016, she served as president of Oriental Infinite Media Co., Ltd., a professional media and event planning company in China. From 1997 to 2005, Ms. Lau served as chairman of Dalian Chronos Information Co., Ltd., a business information consulting company in China. From 1993 to 1996, she served as vice president of Shenzhen Maniche Consulting Company, a management consulting company in China. From 1989 to 1992, Ms. Lau served as general manager assistant of Oriental Textile Industry Co., Ltd., a textile production and processing company in China. Previously, she served as a manager of China Foreign Trade Import and Export Corporation and as business director of Liaoning Textile Import and Export Corporation in China. Prior to that, Ms. Lau served as an accountant at Dalian Steel Plant in China. Ms. Lau received her bachelor’s degree from Dalian University. We believe Ms. Lau is qualified to serve as a director because of her extensive management and investment experience.

~~Jun Liu~~is a member of our board of directors since July 2018. Mr. Liu has served as the president of Beijing Wanfeng Xingye Investment Management Co., Ltd., an investment company in China, since January 2014. From 2004 to January 2014, he served as the president of Zhongansheng Investment Consulting Co, Ltd. From 2002 to 2004, Mr. Liu served as the vice president of Beijing Xingyun Co., Ltd. From 1999 to 2002, Mr. Liu served as the CEO of Weixin (China) Venture Investment Co., Ltd. and the director of Venture Capital Research Center of Renmin University. From 1993 to 1996, Mr. Liu served as government official in the State Auditing Administration. Mr. Liu represented Beijing Xingyun in its acquisition transaction by Pepsi twenty years ago. He also advised Xinhua Media on its reverse merger with Zhizhen Tech (HK: 02371). His investment portfolios cover wide range of sectors, including TMT, education, clean energy, technology, and chemical industries. Mr. Liu received his bachelor degree of Finance and Accounting from Wuhan University in 1989 and received his MBA degree from Renmin University China in 1999. We believe Mr. Liu is qualified to serve as a director because of his extensive financial, investment and M&A experience and the extensive network he has established throughout his career.

~~Pai Liu~~ has served as a member of our board of directors since December 2019. Mr. Liu has served as chief executive officer of Wuhan Dacheng Equity Investment Fund Management Company since July 2016. From December 2014 to April 2016, Mr. Liu was a senior associate of Deloitte in China. From September 2013 to October 2014, Mr. Liu served as a senior associate of Mazars Group in China. From October 2011 to September 2013, Mr. Liu served as an associate of PricewaterhouseCoopers in its Shanghai office and was involved in the auditing of large and medium-sized foreign enterprises. Mr. Liu earned his Master’s degree in accounting & finance from Leeds University in the United Kingdom and received a bachelor’s degree in finance from the South Central University for Nationalities in China. We believe Mr. Liu is qualified to serve as a director because of his extensive management and auditing experience.

~~Number and Terms of Office of Officers and Directors~~

Our Board is divided into two classes with only one class of directors being elected in each year and each class serving a two-year term. The term of office of the first class of directors, consisting of Messrs. Jun Liu and Pai Liu, will expire at the special meeting. The term of office of the second class of directors, consisting of Mr. Chen and Ms. Lau, will expire at the second annual meeting. In accordance with Nasdaq corporate governance requirements, we may not hold an annual meeting of shareholders until after we consummate our initial business combination.

Our officers are appointed by the Board and serve at the discretion of the Board, rather than for specific terms of office. Our Board is authorized to appoint persons to the offices set forth in Amended and Restated Memorandum and Articles of Association as it deems appropriate. Our Amended and Restated Memorandum and Articles of Association provide that our officers may consist of a Chairman of the Board, a Chief Executive Officer, a Chief Financial Officer, a President, Vice Presidents, Secretary, Treasurer, Assistant Secretaries and such other offices as may be determined by the Board.

~~Director Independence~~

NASDAQ listing standards require that a majority of our Board be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s Board, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our Board has determined that Messrs. Jun Liu and Pai Liu and Ms. Lau are “independent directors” as defined in the NASDAQ listing standards and applicable SEC rules. Our audit committee is entirely composed of independent directors meeting NASDAQ’s additional requirements applicable to members of the audit committee. Our independent directors have scheduled meetings at which only independent directors are present.

~~Officer and Director Compensation~~

No compensation will be paid to our sponsor, officers and directors, or any of their respective affiliates, prior to or in connection with the consummation of our initial business combination. Additionally, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our independent directors will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates.

After the completion of our initial business combination, members of our management team who remain with us, may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to shareholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our shareholders in connection with a proposed business combination. It is unlikely the amount of such compensation will be known at the time, as it will be up to the directors of the post-combination business to determine executive and director compensation. Any compensation to be paid to our officers will be determined, or recommended, to Board for determination, either by a committee constituted solely by independent directors or by a majority of the independent directors on our Board.

We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after the initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment.

~~Committees of the Board of Director~~

Our Board has two standing committees: an audit committee and a compensation committee. Subject to phase-in rules and certain limited exceptions, the rules of NASDAQ and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors, and the rules of NASDAQ require that the compensation committee of a listed company be comprised solely of independent directors.

~~Audit Committee~~

We have established an audit committee of the Board. Messrs. Jun Liu and Pai Liu and Ms. Lau are serving as members of our audit committee. Mr. Jun Liu serves as chairman of the audit committee. Under the NASDAQ listing standards and applicable SEC rules, we are required to have at least three members of the audit committee, all of whom must be independent. Messrs. Jun Liu and Pai Liu and Ms. Lau meet the independent director standard under NASDAQ listing standards and under

~~Rule 10-A-3(b)(1) of the Exchange Act.~~

~~Each member of the audit committee is financially literate and our Board has determined that Mr. Jun Liu qualifies as an “audit committee financial expert” as defined in applicable SEC rules.~~

~~We have adopted an audit committee charter, which details the principal functions of the audit committee, including:~~

~~the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm engaged by us;~~

~~pre-approving all audit and permitted non-audit services to be provided by the independent registered public accounting firm engaged by us, and establishing pre-approval policies and procedures;~~

~~reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence;~~

~~setting clear hiring policies for employees or former employees of the independent registered public accounting firm;~~

~~setting clear policies for audit partner rotation in compliance with applicable laws and regulations;~~

obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (i) the independent registered public accounting firm’s internal quality-control procedures, (ii) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues and (iii) all relationships between the independent registered public accounting firm and us to assess the independent registered public accounting firm’s independence;

~~reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and~~

reviewing with management, the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.

~~Compensation Committee~~

We have established a compensation committee of the Board. Messrs. Pai Liu and Jun Liu serve as members of our compensation committee. Mr. Pai Liu serves as chairman of the compensation committee. Under the NASDAQ listing standards and applicable SEC rules, we are required to have at least two members of the compensation committee, all of whom must be independent. Messrs. Jun Liu and Pai Liu and Ms. Lau meet the independent director standard under NASDAQ listing standards applicable to members of the compensation committee.

~~We have adopted a compensation committee charter, which details the principal functions of the compensation committee, including:~~

reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, if any is paid by us, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation in executive session at which the Chief Executive Officer is not present;

~~reviewing and approving the compensation of all of our other officers;~~

~~reviewing our executive compensation policies and plans;~~

~~implementing and administering our incentive compensation equity-based remuneration plans;~~

~~assisting management in complying with our proxy statement and annual report disclosure requirements;~~

~~approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;~~

~~producing a report on executive compensation to be included in our annual proxy statement; and~~

~~reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.~~

The Amended and Restated Memorandum and Articles of Association also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.

~~Director Nominations~~

We do not have a standing nominating committee, though we intend to form a corporate governance and nominating committee as and when required to do so by law or Nasdaq rules. In accordance with Rule 5605(e)(2) of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by the Board. The Board believes that the independent directors can satisfactorily carry out the responsibility of properly selecting or approving director nominees without the formation of a standing nominating committee. The directors who shall participate in the consideration and recommendation of director nominees are Messrs. Jun Liu and Pai Liu and Ms. Lau. In accordance with Rule 5605(e)(1)(A) of the Nasdaq rules, all such directors are independent. As there is no standing nominating committee, we do not have a nominating committee charter in place.

The Board will also consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to stand for election at the next annual meeting of shareholders (or, if applicable, a special meeting of shareholders). Our shareholders that wish to nominate a director for election to the Board should follow the procedures set forth in our Amended and Restated Memorandum and Articles of Association.

We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, the Board considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders.

~~Compensation Committee Interlocks and Insider Participation~~

~~None of our officers currently serves, and in the past year have not served, as a member of the compensation committee of any entity that has one or more officers serving on our Board.~~

~~Code of Ethics~~

We have adopted a Code of Ethics applicable to our directors, officers and employees. We have filed a copy of our Code of Ethics and our audit and compensation committee charters as exhibits to the registration statement filed in connection with our IPO. You can review these documents by accessing our public filings at the SEC’s web site at~~www.sec.gov~~. In addition, a copy of the Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K.

BENEFICIAL OWNERSHIP OF SECURITIES

The following table sets forth certain information regarding the beneficial ownership of Longevity’s ordinary shares as of the record date by:

each person known by us to be the beneficial owner of more than 5% of our outstanding ordinary shares;

each of our current officers and directors; and

all current officers and directors as a group.

As of the record date, there were a total of ~~5,270,000~~2,626,822 ordinary shares (including ~~4,000,000~~1,356,822 public shares). Unless otherwise indicated, all persons named in the table have sole voting and investment power with respect to all ordinary shares beneficially owned by them.

Name and Address of Beneficial Owner⁽¹⁾ Amount and
Nature of
Beneficial
Ownership Approximate
Percentage of
Outstanding
Ordinary
Shares
Whale Management Corporation⁽²⁾⁽³⁾ 1,250,000 23.7 %
Matthew Chen⁽²⁾⁽³⁾ 1,250,000 23.7 %
Teddy Zheng⁽⁴⁾ — —
Jun Liu⁽⁴⁾ — —
Pai Liu⁽⁴⁾ — —
Yukman Lau⁽⁴⁾ — —
All directors and officers as a group 1,250,000 23.7 %
Hudson Bay Capital Management LP⁽⁵⁾ 478,904 8.8 %
HGC Investment Management Inc.⁽⁶⁾ 370,572 6.8 %
Basso Capital Management, L.P.⁽⁷⁾ 315,975 6.0 %
Polar Asset Management Partners Inc.⁽⁸⁾ 340,000 6.5 %
OxFORD ASSET MANAGEMENT LLP⁽⁹⁾ 321,182 6.1 %
Mizuho Financial Group, Inc.⁽¹⁰⁾ 376,976 7.2 %
Glazer Capital, LLC⁽¹¹⁾ 730,049 13.9 %
Name and Address of Beneficial Owner⁽¹⁾ Amount and
Nature of
Beneficial
Ownership Approximate
Percentage
of
Outstanding
Ordinary
Shares
Whale Management Corporation⁽²⁾⁽³⁾ 1,250,000 47.6 %
Matthew Chen⁽²⁾⁽³⁾ 1,250,000 47.6 %
Teddy Zheng⁽⁴⁾⁽⁵⁾ — —
Alex Lyamport⁽⁶⁾ — —
Nicholas H. Adler⁽⁷⁾ — —
Jerry L Hutter⁽⁸⁾ — —
Jun Liu⁽⁴⁾⁽⁹⁾ — —
Pai Liu^(4)(10) — —
Yukman Lau^(4)(11) — —
All directors and officers as a group 1,250,000 47.6 %

(1) Unless otherwise noted, the business address of each of the following entities or individuals is c/o Longevity Acquisition Corporation, Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai, People’s Republic of ~~China District.~~China.

(2) Interests shown consist of founder shares and not ordinary shares underlying the private placement units.

(3) Whale Management Corporation is the record holder of such shares. The shares held by Whale Management Corporation, the Company’s sponsor, are beneficially owned by Matthew Chen, the Company’s Chairman and Chief Executive Officer, who has sole voting and dispositive power over the shares held thereby. Mr. Chen disclaims beneficial ownership over any securities owned by Whale Management Corporation in which he does not have any pecuniary interest. Mr. Chen resigned from his position as the Chief Executive Officer and was appointed as the Chief Financial Officer of the Company on October 22, 2020.

(4) Does not include any shares held by Whale Management Corporation. This individual is a member of Whale Management Corporation, as described in Footnote 3.

(5) ~~Based on a Schedule 13G/A filed with the SEC on February 4, 2019. Hudson Bay Capital Management LP, a Delaware limited partnership (“Hudson Bay”), serves~~Resigned from his position as the investment manager to Hudson Bay Master Fund Ltd., in whose name the shares reported therein are held. As such, Hudson Bay may be deemed to be the beneficial owner of all shares held by Hudson Bay Master Fund Ltd. Sander Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay. Mr. Gerber disclaims beneficial ownership of these securities. The addressChief Financial Officer of the ~~principal business office of each of the reporting persons is 777 Third Avenue, 30th Floor, New York, NY 10017.~~Company on October 22, 2020.

(6) ~~Based on a Schedule 13G filed with~~Appointed as the ~~SEC on February 13, 2019, on behalf of HGC Investment Management Inc. a company incorporated under the laws of Canada. The principal office~~Chief Executive Officer of the ~~shareholder is 366 Adelaide, Suite 601,~~Company and ~~Toronto, Ontario M5V 1R9, Canada.~~Director of the Board on October 22, 2020.

(7) ~~Based~~Appointed as an Independent Director and the Chairman of the compensation committee of the Board on ~~a Schedule 13G/A filed on February 7,~~October 22, 2020. Such shares are directly beneficially owned by Basso SPAC Fund LLC (“Basso SPAC”), a Delaware limited liability company. Basso Management, LLC (“Basso Management”), a Delaware limited liability company, is the manager of Basso SPAC. Basso Capital Management, L.P. (“BCM”), a Delaware limited partnership, serves as the investment manager of Basso SPAC. Basso GP, LLC (“Basso GP”), a Delaware limited liability company, is the general partner of BCM. Howard I. Fischer is the sole portfolio manager for Basso SPAC, the Chief Executive Officer and a founding managing partner of BCM, and a member of each of Basso Management and Basso GP. Accordingly, each of Basso Management, BCM, Basso GP and Mr. Fischer may be deemed to indirectly beneficially own such shares. The business address of each such persons is 650 Fifth Avenue, New York, New York 10019.

(8) ~~Based~~Appointed as an Independent Director and the Chairman of the audit committee of the Board on ~~a Schedule 13G filed on February 11,~~October 22, 2020. Such shares are directly beneficially owned by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to shares directly held by PMSMF. The business address of each such persons is 401 Bay Street, Suite 1900, PO Box 19, Toronto, Ontario M5H 2Y4, Canada.

(9) ~~Based~~Resigned from his positions as an Independent Director and the Chairman of the compensation committee of the Board on ~~a Schedule 13G filed on February 13,~~October 22, 2020. Such shares are directly beneficially owned by OxFORD Asset Management LLP (“OxFORD”) held for the account of OxAM Quant Fund Limited, a Cayman Islands exempted company (“OxAM”). OxFORD serves as investment adviser to OxAM. The business address of each such persons is OxAM House, 6 George Street, Oxford, United Kingdom, OX1 2BW.

(10) Based on a Schedule 13G filed on February 14, 2020. Such shares are directly beneficially owned by Mizuho Financial Group, Inc. on behalf of its subsidiaries, Mizuho Bank, Ltd, Mizuho Americas LLC and Mizuho Securities USA LLC. The business addressResigned from his position as the Chairman of the ~~reporting entity is 1–5–5, Otemachi, Chiyoda–ku, Tokyo 100–8176, Japan.~~audit committee of the Board on October 22, 2020.

(11) ~~Based on a Schedule 13G filed on April 9, 2020. Such shares are held by certain funds and managed accounts to which Glazer Capital, LLC serves~~Resigned from his position as ~~investment manager. The business address~~an Independent Director of the ~~reporting entity is 250 West 55th Street, Suite 30A, New York, New York 10019.~~Board on October 22, 2020.


24
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

In June 2018 we issued an aggregate of 1,150,000 founder shares to our sponsor for an aggregate purchase price of $25,000 in cash, or approximately $0.022 per share. 150,000 founder shares were forfeited by our sponsor on October 12, 2018 because the underwriters’ over-allotment option was not exercised.

Subject to certain limited exceptions, our initial shareholders have agreed not to transfer, assign or sell their founder shares until the earlier of (A) one year after the completion of our initial business combination or (B) subsequent to our initial business combination, (x) if the last sale price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property.

Our sponsor purchased an aggregate of 250,000 private placement units in a private placement that occurred simultaneously with the closing of our initial public offering. Our sponsor has agreed not to transfer, assign or sell any of the shares included in the private placement units and the respective ordinary shares underlying the rights and warrants included in the private placement units until 30 days after the completion of our initial business combination.

An affiliate of our sponsor agreed, from the date that our securities were first listed on Nasdaq through the earlier of our consummation of our initial business combination and our liquidation, to make available to us office space, utilities and secretarial and administrative services, as we may require from time to time. We pay such affiliate $10,000 per month, which funds are used to pay for the aforementioned services. We believe, based on rents and fees for similar services in Shanghai, China, that the fee charged by such affiliate is at least as favorable as we could have obtained from an unaffiliated person. One of such affiliate’s executive officers is a member of our sponsor.

Other than reimbursement of any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations, no compensation or fees of any kind, including finder’s fees, consulting fees, non-cash payments or other similar compensation, will be paid to our officers or directors, or to any of their respective affiliates, prior to or with respect to our initial business combination (regardless of the type of transaction that it is). Our independent directors are responsible for reviewing and approving all related party transactions as defined under Item 404 of Regulation S-K, after reviewing each such transaction for potential conflicts of interests and other improprieties.

Prior to the closing of our initial public offering, our sponsor had also loaned to us an aggregate of $202,415 to cover expenses related to our initial public offering. These loans were non-interest bearing and will be payable without interest on demand. We repaid these loans from the proceeds of our initial public offering not placed in the trust account.

In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or our officers and directors may, but are not obligated to, loan us funds as may be required. If we consummate our initial business combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use a portion of the offering proceeds held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Such loans would be evidenced by promissory notes. The notes would either be paid upon consummation of our initial business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of the notes may be converted upon consummation of our business combination into additional private placement units at a price of $10.00 per unit (which, for example, would result in the holders being issued 165,000 ordinary shares if $1,500,000 of notes were so converted (including 15,000 shares upon the closing of our initial business combination in respect of 150,000 rights included in such units), as well as 150,000 warrants to purchase 75,000 shares).

After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to our shareholders, to the extent then known, in the tender offer or proxy solicitation materials, as applicable, furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a shareholder meeting held to consider our initial business combination, as applicable, as it will be up to the directors of the post-combination business to determine executive and director compensation.

25
All ongoing and future transactions between us and any member of our management team or his or her respective affiliates will be on terms believed by us at that time, based upon other similar arrangements known to us, to be no less favorable to us than are available from unaffiliated third parties. It is our intention to obtain estimates from unaffiliated third parties for similar goods or services to ascertain whether such transactions with affiliates are on terms that are no less favorable to us than are otherwise available from such unaffiliated third parties. If a transaction with an affiliated third party were found to be on terms less favorable to us than with an unaffiliated third party, we would not engage in such transaction.

We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek to complete our initial business combination with a target that is affiliated with our sponsor, officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent accounting firm, or independent investment banking firm that our initial business combination is fair to our company from a financial point of view.

We have entered into a registration rights agreement. Our initial shareholders and the underwriter of our initial public offering and their permitted transferees can demand, after we consummates our initial business combination, that we register the founder shares, the private units and underlying securities, the shares underlying the warrants underlying the unit purchase option being issued to the underwriters of our initial public offering, and any securities issued upon conversion of working capital loans, pursuant to such agreement. In addition, the holders have certain “piggy-back” registration rights on registration statements filed after the Company’s consummation of our initial business combination. Notwithstanding the foregoing, the underwriter of our initial public offering may not exercise its demand and “piggyback” registration rights after five (5) and seven (7) years after August 28, 2018 and may not exercise its demand rights on more than one occasion.

26

SHAREHOLDER PROPOSALS

If you are a shareholder and you want to include a proposal in the proxy statement for the 2021 annual general meeting, your proposals are required to be submitted to Longevity by no later than
~~, 2020.~~ January 21, 2021.

If the Extension Proposal is not approved, there will be no annual general meeting in 2021.

The Board will also consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to stand for election at the next annual meeting of shareholders (or, if applicable, a special meeting of shareholders). Our shareholders that wish to nominate a director for election to the Board should follow the procedures set forth in our Amended and Restated Memorandum and Articles of Association.

DELIVERY OF DOCUMENTS TO SHAREHOLDERS

Pursuant to the rules of the SEC, Longevity and its agents that deliver communications to its shareholders are permitted to deliver to two or more shareholders sharing the same address a single copy of Longevity’s proxy statement. Upon written or oral request, Longevity will deliver a separate copy of the proxy statement to any shareholder at a shared address who wishes to receive separate copies of such documents in the future. Shareholders receiving multiple copies of such documents may likewise request that Longevity deliver single copies of such documents in the future. Shareholders may notify Longevity of their requests by calling or writing Longevity at Longevity’s principal executive offices at Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai, People’s Republic of ~~China District.~~China.

WHERE YOU CAN FIND MORE INFORMATION

Longevity files reports, proxy statements and other information with the SEC as required by the Securities Exchange Act of 1934, as amended. Longevity files its reports, proxy statements and other information electronically with the SEC. You may access information on Longevity at the SEC website containing reports, proxy statements and other information at http://www.sec.gov.

You may obtain this additional information, or additional copies of this proxy statement, at no cost, and you may ask any questions you may have about the ~~Director Proposal,~~ Extension Proposal or the Adjournment Proposal by contacting us at the following address, telephone number or facsimile number:

Longevity Acquisition Corporation

Yongda International Tower
No. 2277 Longyang Road,
Pudong District, Shanghai
People’s Republic of China ~~District~~
Tel: (86) 21-60832028

or:

Advantage Proxy, Inc.
P.O. Box 13581
Des Moines, WA 98198
Attn: Karen Smith
Toll Free: (877) 870-8565
Collect: (206) 870-8565

In order to receive timely delivery of the documents in advance of the special meeting, you must make your request for information no later than ,November 13, 2020.

27
ANNEX A

LONGEVITY ACQUISITION
CORPORATION (the “Company”)
RESOLUTIONS OF THE SHAREHOLDERS OF THE COMPANY

Extension Proposal

The Amended and Restated Memorandum and Articles of Association of Longevity Acquisition Corporation shall be amended by deleting Regulation 23.2 in its entirety and replacing it with the following:

“23.2 The Company has until ~~November 30, 2020~~May 29, 2021, or such earlier date as may be determined by the Board, to consummate a Business Combination. In the event that the Company does not consummate a Business Combination by such date, such failure shall trigger an automatic redemption of the Public Shares (an Automatic Redemption Event) and the Directors of the Company shall take all such action necessary (i) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares or distribute the Trust Account to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (ii) as promptly as practicable, to cease all operations except for the purpose of making such distribution and any subsequent winding up of the Company's affairs. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.”

Adjournment Proposal

It is resolved to direct the chairman of the Meeting to adjourn the Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Meeting, there are not sufficient votes to approve the Extension Proposal.

A-1
PROXY

LONGEVITY ACQUISITION CORPORATION

Yongda International
Tower No. 2277
Longyang Road
Pudong District
Shanghai, People’s Republic of China ~~District~~

SPECIAL MEETING OF SHAREHOLDERS

,NOVEMBER 20, 2020

YOUR VOTE IS IMPORTANT
FOLD AND DETACH HERE

LONGEVITY ACQUISITION CORPORATION

THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 20, 2020

The undersigned, revoking any previous proxies relating to these shares, hereby acknowledges receipt of the Notice and Proxy Statement, dated ,October 26, 2020, in connection with the special meeting and at any adjournments thereof (the “Meeting”) to be held at ~~10:~~11:00 a.m. Eastern Time on ,November 20, 2020 at the offices of Longevity’s counsel, ~~Ellenoff Grossman~~Hunter Taubman Fischer & ~~Schole LLP, 1345~~Li LLC, 800 Third Avenue, ~~of the Americas, 11th Floor,~~Suite 2800, New York, ~~NY 10105,~~New York 10022, and hereby appoints Alex Lyamport and Matthew Chen, ~~and Teddy Zheng,~~ and each of them (with full power to act alone), the attorneys and proxies of the undersigned, with power of substitution to each, to vote all ordinary shares of Longevity Acquisition Corporation (the “Company”) registered in the name provided, which the undersigned is entitled to vote at the Meeting with all the powers the undersigned would have if personally present. Without limiting the general authorization hereby given, said proxies are, and each of them is, instructed to vote or act as follows on the proposals set forth in this Proxy Statement.

THIS PROXY, WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” PROPOSAL 1 ~~“FOR” EACH DIRECTOR NOMINEE~~ AND “FOR” PROPOSAL 3.2.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL 1 ~~“FOR” EACH DIRECTOR NOMINEE~~ AND “FOR” PROPOSAL 3.2.

Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Shareholders to be held on ~~, 2020:~~November 20, 2020: This notice of meeting and the accompany proxy statement are available at ~~____________________.~~https://www.cstproxy.com/longevityacquisitioncorp/2020.

Proposal 1 — Extension Proposal FOR
¨ AGAINST
¨ ABSTAIN
¨
Amend Longevity’s Amended and Restated Memorandum and Articles of Association to extend the date by Longevity must consummate a business combination to ~~November 30, 2020,~~May 29, 2021, by amending the Amended and Restated Memorandum and Articles of Association to delete the existing Regulation 23.2 thereof and replacing it with the new Regulation 23.2 in the form set forth in Annex A of the accompanying proxy statement.

Proposal 2 — ~~Director~~Adjournment Proposal
~~To elect each of Messrs. Jun Liu and Pai Liu as Class I directors of the Company.~~
FOR
~~ALL~~ ¨
¨
~~WITHHOLD~~
~~ALL~~ ¨
~~FOR ALL~~
EXCEPT*
¨
* Instruction: To withhold authority to vote for any individual nominee, mark the “For All Except” box above and write that nominee’s name on the line provided below.

~~Proposal 3 — Adjournment Proposal~~ ~~FOR~~
¨ AGAINST
¨ ABSTAIN
¨
To direct the chairman of the special meeting to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Extension ~~Proposal and the Director~~ Proposal.

Regardless of whether you vote “FOR” or “AGAINST” Proposal 1 or “ABSTAIN,” or whether they were holders of Longevity ordinary shares on the record date or acquired such shares after such date, if you hold ordinary shares issued in the Company’s IPO, or public shares, you may exercise your redemption rights with respect to all or a portion of your public ~~shares by marking the “Exercise Redemption Rights” box below and indicating how many public shares for which you are exercising such redemption rights in the space provided.~~shares. If you exercise your redemption rights, then you will be exchanging the indicated number of your public shares for cash and you will no longer own such public shares. YOU WILL ONLY BE ENTITLED TO RECEIVE CASH FOR THOSE PUBLIC SHARES IF YOU TENDER YOUR SHARE CERTIFICATES REPRESENTING SUCH REDEEMED PUBLIC SHARES TO THE COMPANY’S TRANSFER AGENT AT LEAST TWO BUSINESS DAYS PRIOR TO THE VOTE AT SUCH MEETING.
~~EXERCISE REDEMPTION RIGHTS~~¨

Dated: __________, 2020

Shareholder’s Signature

Shareholder’s Signature

Signature should agree with name printed hereon. If shares are held in the name of more than one person, EACH joint owner should sign. Executors, administrators, trustees, guardians, and attorneys should indicate the capacity in which they sign. Attorneys should submit powers of attorney.

PLEASE SIGN, DATE AND RETURN THE PROXY IN THE ENVELOPE ENCLOSED TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY. THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED SHAREHOLDER. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “FOR” PROPOSAL 1 ~~“FOR” EACH DIRECTOR NOMINEE~~ AND “FOR” PROPOSAL 3.2. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU.

x¨	Preliminary Proxy Statement

¨	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨x	Definitive Proxy Statement

¨	Definitive Additional Materials

¨	Soliciting Material Pursuant to Section 240.14a-12

	(1) Title of each class of securities to which transaction applies:


	(2) Aggregate number of securities to which transaction applies:


	(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):


	(4) Proposed maximum aggregate value of transaction:


	(5) Total fee paid:

	(1) Amount Previously Paid:


	(2) Form, Schedule or Registration Statement No.:


	(3) Filing Party:


	(4) Date Filed:

~~May ,~~October 26, 2020	By Order of the Board of Directors

	/s/ Matthew Chen
	Chief ~~Executive~~Financial Officer

TABLE OF CONTENTS

	Page

QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING	1

FORWARD-LOOKING STATEMENTS	119

BACKGROUND	1210

NOT TO SEEK APPROVAL ON THE PROPOSED BUSINESS COMBINATION	16

THE EXTENSION PROPOSAL	13

~~THE DIRECTOR PROPOSAL~~	1817

THE ADJOURNMENT PROPOSAL	19

~~MANAGEMENT~~	2122

BENEFICIAL OWNERSHIP OF SECURITIES	2624

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS	2925

SHAREHOLDER PROPOSALS	3127

DELIVERY OF DOCUMENTS TO SHAREHOLDERS	3127

WHERE YOU CAN FIND MORE INFORMATION	3127

ANNEX A: PROPOSED AMENDMENT TO THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF LONGEVITY ACQUISITION CORP	A-1

x	No fee required.

¨	Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.

Q.	*Why am I receiving this proxy statement?*	A.	This proxy statement and the accompanying materials are being sent to you in connection with the solicitation of proxies by the Board, for use at the special meeting ~~in lieu of the 2020 annual general meeting~~ of shareholders to be held on ~~, May ,~~Friday, November 20, 2020 at ~~10:~~11:00 a.m., Eastern Time, at the ~~offices~~officers of Longevity’s counsel, ~~Ellenoff Grossman~~Hunter Taubman Fischer & ~~Schole LLP, 1345~~Li LLC, 800 Third Avenue, ~~of the Americas, 11~~^th ~~Floor,~~Suite 2800, New York, New York ~~10105,~~10022, or at any adjournments or postponements thereof. This proxy statement summarizes the information that you need to make an informed decision on the proposals to be considered at the special meeting.

			We intend to hold the special meeting in person. However, we are actively monitoring the coronavirus (COVID-19) pandemic. We are sensitive to the public health and travel concerns our shareholders may have and the protocols that federal, state, and local governments may impose. In the event it is not possible or advisable to hold the special meeting in person, we will announce alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication.

			Longevity is a blank check company formed in March 2018 for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, exchangeable share transaction or other similar business transaction with one or more operating businesses or assets. On August 31, 2018, we consummated our IPO of 4,000,000 units at a price of $10.00 per unit, generating gross proceeds of $40,000,000. Simultaneously with the closing of the IPO, we consummated the private sale of 270,000 units (the “private placement units”) to our sponsor and the underwriter of our IPO at a price of $10.00 per unit, generating gross proceeds of $2,700,000. A total of $40,000,000 was placed in the trust account. Like most blank check companies, our Amended and Restated Memorandum and Articles of Association provides for the return of the IPO proceeds held in trust to the public shareholders if there is no qualifying business combination consummated on or before a certain date. ~~The~~ On October 21, 2020, Longevity entered into the Merger Agreement with 4D Pharma and Merger Sub, providing for, among other things, and subject to the conditions therein, the combination of Longevity and 4D Pharma pursuant to the proposed merger of Longevity with and into Merger Sub with Merger Sub continuing as the surviving entity and wholly-owned subsidiary of 4D Pharma. Our Board believes therefore that it is in the best interests of the shareholders to continue ~~Longevity’s~~our existence until the Extended Date in order to allow ~~Longevity~~us more time to complete anour initial business combination. ~~In addition, we are proposing the election of two directors to the Board to serve as Class I directors of the Company.~~

Q.	*What is being voted on?*	A.	You are being asked to vote on:

			•	a proposal to amend Longevity’s Amended and Restated Memorandum and Articles of Association to extend the date by which Longevity must consummate a business combination from ~~May 29, 2020 to~~ November 30, 2020 to May 29, 2021, or such earlier date as determined by the Board (the “Extended Date”), by amending the Amended and Restated Memorandum and Articles of Association to delete the existing Regulation 23.2 thereof and replacing it with the new Regulation 23.2 in the form set forth in Annex A of the accompanying proxy statement (the “Extension ~~Proposal”);~~

				•	~~a proposal to elect each of Messrs. Jun Liu and Pai Liu as Class I directors of the Company (the “Director~~ Proposal”); and

				•	a proposal to direct the chairman of the special meeting to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Extension Proposal ~~or the Director Proposal~~ (the “Adjournment Proposal”).

				The Extension Proposal is essential to the overall implementation of our Board’s plan to extend the date by which we have to complete a business combination. Approval of the Extension Proposal is a condition to the implementation of the Extension.

Q.	*Why is the Company proposing the Extension Proposal?*	A.	Longevity’s Amended and Restated Memorandum and Articles of Association provides for the return of the IPO proceeds held in trust to public shareholders if there is no qualifying business combination consummated on or before ~~May 29,~~November 30, 2020.

			~~While~~ On October 21, 2020, Longevity entered into the Merger Agreement with 4D Pharma and Merger Sub, providing for, among other things, and subject to the conditions therein, the combination of Longevity and 4D Pharma pursuant to the proposed merger of Longevity with and into Merger Sub with Merger Sub continuing as the surviving entity and wholly-owned subsidiary of 4D Pharma. Our Board believes therefore that it is ~~currently~~ in ~~discussions with respect~~the best interests of the shareholders to ~~business combination opportunities, Longevity has not yet executed a definitive agreement for a~~continue our existence until the Extended Date in order to allow us more time to complete our initial business combination. ~~Longevity currently anticipates entering into such an agreement with one of its prospective targets, but does not expect be able to consummate such a business combination by May 29, 2020.~~

			Because Longevity may not be able to conclude a business combination within the permitted time period, Longevity has determined to seek shareholder approval to extend the date by which Longevity must complete a business combination.

Q.	*Why should I vote for the Extension Proposal?*	A.	The Board believes that given Longevity’s expenditure of time, effort and money on finding a business combination, circumstances warrant providing public shareholders an opportunity to consider a business combination to date. Accordingly, our Board is proposing the Extension Proposal to extend the date by which Longevity must complete a business combination until the Extended Date and to allow for the Election.


			Longevity’s Amended and Restated Memorandum and Articles of Association require the affirmative vote of the holders of at least 65% of the Company’s ordinary shares which are present (in person or by proxy) and which vote at the special meeting in order to effect an amendment to certain of its provisions, including any amendment that would extend its corporate existence beyond ~~May 29,~~November 30, 2020, except in connection with, and effective upon consummation of, a business combination. Additionally, Longevity’s Amended and Restated Memorandum and Articles of Association and Trust Agreement require that all public shareholders have an opportunity to redeem their public shares in the case Longevity’s corporate existence is extended as described above. We believe that these Amended and Restated Memorandum and Articles of Association provisions were included to protect Longevity shareholders from having to sustain their investments for an unreasonably long period if Longevity failed to find a suitable business combination in the timeframe contemplated by the Amended and Restated Memorandum and Articles of Association. We also believe, however, that given Longevity’s expenditure of time, effort and money on the potential business combinations with the targets it has identified, circumstances warrant providing those who would like to consider whether a potential business combination with one or more of such targets is an attractive investment with an opportunity to consider such transaction, inasmuch as Longevity is also affording shareholders who wish to redeem their public shares the opportunity to do so, as required under its Amended and Restated Memorandum and Articles of Association. Accordingly, we believe the Extension is consistent with Longevity’s Amended and Restated Memorandum and Articles of Association and IPO prospectus.

Q.	*~~How does the Board recommend that I vote on the Director Proposal?~~*	A.	~~The Board recommends that you vote “FOR” each of Messrs. Jun Liu and Pai Liu to serve as Class I directors of the Company.~~

Q.	*How do the Longevity insiders intend to vote their shares?*	A.	All of Longevity’s directors, executive officers, initial shareholders and their respective affiliates are expected to vote any ordinary shares over which they have voting control (including any public shares owned by them) in favor of the Extension Proposal, and the Adjournment ~~Proposal and the election of each of Messrs. Jun Liu and Pai Liu to serve as Class I directors of the Company.~~ Proposal. Longevity’s directors, executive officers, initial shareholders and their respective affiliates are not entitled to redeem the founder shares. Public shares purchased on the open market by Longevity’s directors, executive officers and their respective affiliates may be redeemed. On the record date, Longevity’s directors, executive officers, initial shareholders and their affiliates beneficially owned and were entitled to vote 1,000,000 founder shares and 250,000 private placement units, representing approximately ~~23.7%~~47.6% of Longevity’s issued and outstanding ordinary shares. Longevity’s directors, executive officers, initial shareholders and their affiliates did not beneficially own any public shares as of such date.


Q.	*What amount will holders receive upon consummation of a subsequent business combination or liquidation if the Extension Proposal is approved?*	A.	If the Extension Proposal is approved, our sponsor, or its designees, has agreed to contribute to us as a loan (i) $0.025 for each public share that is not redeemed in connection with the shareholder vote on the Extension Proposal (the “Initial Contribution”) plus (ii) $0.025 for each public share that is not redeemed for each subsequent calendar month (commencing on the 30^th day of each subsequent month), or portion thereof, that is needed by Longevity to complete an initial business combination from ~~May 29,~~November 30, 2020 (the date by which Longevity is currently required to complete its business combination) until the Extended Date (the “Additional Contributions” and, collectively with the Initial Contribution, the “Contributions”). For example, if Longevity takes until November 30, 2020 to complete its business combination, which would represent calendar months, our sponsor, or its designees, would make aggregate maximum Contributions of approximately $600,000, or $0.15 per share (assuming no public shares were redeemed). Assuming the Extension Proposal is approved, the Initial Contribution will be deposited in the trust account promptly following the special meeting. Each Additional Contribution will be deposited in the trust account established in connection with the IPO within thirty calendar days from the beginning of such calendar month (or portion thereof). Accordingly, if the Extension Proposal is approved and the Extension is implemented and the Company takes the full time through the Extended Date to complete the initial business combination, the redemption amount per share at the meeting for such business combination or the Company’s subsequent liquidation will be approximately $10.75 per share, in comparison to the current redemption amount of approximately ~~$10.60~~$10.74 per share (as of ~~February 29,~~October 9, 2020 and assuming no public shares were redeemed in connection with the Extension Proposal). The Contributions are conditioned upon the implementation of the Extension Proposal. The Contributions will not occur if the Extension Proposal is not approved or the Extension is abandoned. The amount of the Contributions will not bear interest and will be repayable by us to our sponsor or its designees upon consummation of an initial business combination. If our sponsor or its designees advises us that it does not intend to make the Contributions, then the Extension Proposal ~~the Director Proposal~~ and the Adjournment Proposal will not be put before the shareholders at the special meeting and we will dissolve and liquidate in accordance with our Amended and Restated Memorandum and Articles of Association. Our sponsor or its designees will have the sole discretion whether to continue extending for additional calendar months until the Extended Date and if our sponsor determines not to continue extending for additional calendar months, its obligation to make additional Contributions will terminate.

Q.	*What vote is required to adopt the Extension Proposal?*	A.	Pursuant to Longevity’s Memorandum and Articles of Association, approval of the Extension Proposal will require the affirmative vote of at least 65% of the Company’s ordinary shares entitled to vote which are present (in person or by proxy) at the special meeting and which vote on the Extension Proposal will be required to approve the Extension Proposal. Abstentions will have no effect with respect to approval of this proposal.

Q.	*What vote is required to approve the ~~Director Proposal and the~~ Adjournment Proposal?*	A.	The affirmative vote of a majority of the Company’s ordinary shares entitled to vote and which are present (in person or by proxy) at the special meeting and which voted on the Director Proposal will be required to elect each of the two nominees as directors. Abstentions will have no effect with respect to approval of this proposal. The affirmative vote of a majority of the Company’s ordinary shares entitled to vote and which are present (in person or by proxy) at the special meeting and which voted will be required to direct the chairman to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Extension ~~Proposal or the Director~~ Proposal. Abstentions will have no effect with respect to approval of this proposal.

			If your shares are held by your broker as your nominee (that is, in “street name”), you may need to obtain a proxy form from the institution that holds your shares and follow the instructions included on that form regarding how to instruct your broker to vote your shares. If you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items, but not with respect to “non-discretionary” items. Discretionary items are proposals considered routine under the rules of the New York Stock Exchange applicable to member brokerage firms. These rules provide that for routine matters your broker has the discretion to vote shares held in street name in the absence of your voting instructions. On non-discretionary items for which you do not give your broker instructions, the shares will be treated as broker non-votes. We believe that each of the proposals are “non-discretionary” items.

Q.	*What if I don’t want to vote for the Extension Proposal?*	A.	If you do not want the Extension Proposal to be approved, you should vote against the Extension Proposal. If the Extension Proposal is approved, and the Extension is implemented, and you have exercised your redemption rights then the Withdrawal Amount will be withdrawn from the trust account and paid to you and the other redeeming public shareholders.

Q.	*Will you seek any further extensions to liquidate the trust account?*	A.	Other than the extension until the Extended Date as described in this proxy statement, Longevity does not anticipate, but is not prohibited from, seeking the requisite shareholder consent to any further extension to consummate a business combination. Longevity has provided that all holders of public shares, whether they vote for or against the Extension Proposal, or whether they were holders of Longevity ordinary shares on the record date or acquired such shares after such date, may elect to redeem their public shares into their pro rata portion of the trust account and should receive the funds shortly after the special meeting. Those holders of public shares who elect not to redeem their shares now shall retain redemption rights with respect to the initial business combinations, or, if no future business combination is brought to a vote of the shareholders or if a business combination is not completed for any reason, such holders shall be entitled to the pro rata portion of the trust account on the Extended Date upon a liquidation of the Company.


Q.	*What happens if the Extension Proposal is not approved?*		A.	If the Extension Proposal is not approved and we have not consummated a business combination by ~~May 29,~~November 30, 2020, or if the Extension Proposal is approved and we have not consummated a business combination by the Extended Date, we will (a) cease all operations except for the purpose of winding up, (b) as promptly as reasonably possible but no more than five (5) Business Days thereafter, subject to lawfully available funds therefor, redeem 100% of the outstanding public shares, at a per-share price, payable in cash, equal to the amount then on deposit in the trust account, including interest earned thereon not previously released to us for the payment of taxes (less up to $50,000 of interest to pay liquidation expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (c) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and the Board, dissolve and liquidate, subject (in the case of (b) and (c) above) to our obligations to provide for claims of creditors and the requirements of other applicable law.

			The initial shareholders have waived their rights to participate in any liquidation distribution with respect to their founder shares or the ordinary shares included in the private placement units. There will be no distribution from the trust account with respect to our warrants or rights, which will expire worthless in the event we wind up.

Q.	*If the Extension Proposal is approved, what happens next?*	A.	If the Extension Proposal is approved, the Company has until the Extended Date to complete its initial business combination. If the Extension Proposal is approved, we will, pursuant to that certain Investment Management Trust Agreement (the “Trust Agreement”) between us and Continental Stock Transfer & Trust Company, remove the Withdrawal Amount from the trust account, deliver to the holders of redeemed public shares their portion of the Withdrawal Amount and retain the remainder of the funds in the trust account for our use in connection with consummating a business combination on or before the Extended Date.

			We will not implement the Extension if we would not have at least $5,000,001 of net tangible assets following approval of the Extension Proposal, after taking into account the Election.

			If the Extension Proposal is approved and the Extension is implemented, the removal of the Withdrawal Amount from the trust account in connection with the Election will reduce the amount held in the trust account following the Election. We cannot predict the amount that will remain in the trust account if the Extension Proposal is approved and the amount remaining in the trust account may be only a small fraction of the approximately ~~$41.9~~$14.6 million that was in the trust account as of ~~November 30, 2019.~~October 9, 2020. In such event, we may need to obtain additional funds to complete an initial business combination, and there can be no assurance that such funds will be available on terms acceptable to the parties or at all.


			The Company will remain a reporting company under the Securities Exchange Act of 1934 (the “Exchange Act”) and its units, ordinary shares, rights and warrants will remain publicly traded.

			If the Extension Proposal is approved and public shareholders elect to redeem their public shares, the removal of the Withdrawal Amount from the trust account will reduce the amount remaining in the trust account and increase the percentage interest of Longevity’s ordinary shares held by Longevity’s officers, directors, initial shareholders and their affiliates.

Q.	*Who bears the cost of soliciting proxies?*	A.	The Company will bear the cost of soliciting proxies and will reimburse brokerage firms and others for expenses involved in forwarding proxy materials to beneficial owners or soliciting their execution. In addition to solicitations by mail, the Company, through their respective directors and officers, may solicit proxies in person, by telephone or by electronic means. Such directors and officers will not receive any special remuneration for these efforts. We have retained Advantage Proxy, Inc. (“Advantage Proxy”) to assist us in soliciting proxies. If you have questions about how to vote or direct a vote in respect of your shares, you may contact Advantage Proxy at (877) 870-8565 (toll free) or by email at ksmith@advantageproxy.com. The Company has agreed to pay Advantage Proxy a fee of $6,500 and expenses, for its services in connection with the special meeting.

Q.	*How do I change my vote?*	A.	If you have submitted a proxy to vote your shares and wish to change your vote, you may do so by delivering a later-dated, signed proxy card to Longevity’s Secretary prior to the date of the special meeting or by voting in person at the special meeting. Attendance at the special meeting alone will not change your vote. You also may revoke your proxy by sending a notice of revocation to Longevity Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai, People’s Republic of China, ~~District,~~ Attn: Secretary.

Q.	*If my shares are held in “street name,” will my broker automatically vote them for me?*	A.	No. If you do not give instructions to your broker, your broker can vote your shares with respect to “discretionary” items, but not with respect to “non-discretionary” items. We believe that each of the proposals are “non-discretionary” items. Your broker can vote your shares with respect to “non-discretionary items” only if you provide instructions on how to vote. You should instruct your broker to vote your shares. Your broker can tell you how to provide these instructions. If you do not give your broker instructions, your shares will be treated as broker non-votes and will have the effect of a vote “AGAINST” the Extension Proposal and will have no effect on the other proposals.

Q.	*What is a quorum requirement?*	A.	A quorum of shareholders is necessary to hold a valid meeting. A quorum will be present for the special meeting if there are present in person or by proxy not less than a majority of the Company’s ordinary shares present at the meeting in person or by proxy.


			Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you attend the special ~~meeting in person.~~meeting. Abstentions will be counted towards the quorum requirement. If there is no quorum, the chairman of the special meeting may adjourn the special meeting to another date.

Q.	*Who can vote at the special meeting?*	A.	Only holders of record of Longevity’s ordinary shares at the close of business on ~~April 29,~~October 9, 2020 are entitled to have their vote counted at the special meeting and any adjournments or postponements thereof. On this record date, ~~5,270,000~~2,626,822 ordinary shares were outstanding and entitled to vote.

			Shareholder of Record: Shares Registered in Your Name.If on the record date your shares were registered directly in your name with Longevity’s transfer agent, Continental Stock Transfer & Trust Company, then you are a shareholder of record. As a shareholder of record, you may vote in person at the special meeting or vote by proxy. Whether or not you plan to attend the special meeting, ~~in person,~~ we urge you to fill out and return the enclosed proxy card to ensure your vote is counted.

			Beneficial Owner: Shares Registered in the Name of a Broker or Bank. If on the record date your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the special meeting. However, since you are not the shareholder of record, you may not vote your shares ~~in person~~ at the special meeting unless you request and obtain a valid proxy from your broker or other agent.

Q.	*Does the Board recommend voting for the approval of the Extension Proposal ~~the Director Proposal~~ and the Adjournment Proposal?*	A.	Yes. After careful consideration of the terms and conditions of these proposals, the Board has determined that the Extension ~~Proposal, the Director~~ Proposal and the Adjournment Proposal are fair to and in the best interests of Longevity and its shareholders. The Board recommends that Longevity’s shareholders vote “FOR” the Extension Proposal ~~“FOR” each director nominee~~ and “FOR” the Adjournment Proposal.


Q.	*What happens to the Longevity warrants and rights if the Extension Proposal is not approved?*	A.	If the Extension Proposal is not approved, we will automatically wind up, liquidate and dissolve effective starting on ~~May 29,~~November 30, 2020. In such event, your warrants and rights will become worthless.

Q.	*What happens to the Longevity warrants and rights if the Extension Proposal is approved?*	A.	If the Extension Proposal is approved, Longevity will continue to attempt to consummate an initial business combination with potential targets until the Extended Date, and will retain the blank check company restrictions previously applicable to it. The warrants and rights will remain outstanding in accordance with their terms.

Q.	*What do I need to do now?*	A.	Longevity urges you to read carefully and consider the information contained in this proxy statement, including the annex, and the Annual Report on Form 10-K and to consider how the proposals will affect you as a Longevity shareholder. You should then vote as soon as possible in accordance with the instructions provided in this proxy statement and on the enclosed proxy card.

Q.	*How do I vote?*	A.	If you are a holder of record of Longevity public shares, you may vote in person at the special meeting or by submitting a proxy for the special meeting. Whether or not you plan to attend the special meeting, ~~in person,~~ we urge you to vote by proxy to ensure your vote is counted. You may submit your proxy by completing, signing, dating and returning the enclosed proxy card in the accompanying pre-addressed postage paid envelope. You may still attend the special meeting and vote in person if you have already voted by proxy.

			If your shares of Longevity are held in “street name” by a broker or other agent, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the special meeting. However, since you are not the shareholder of record, you may not vote your shares ~~in person~~ at the special meeting unless you request and obtain a valid proxy from your broker or other agent.

Q.	*How do I exercise my redemption rights?*	A.	If the Extension is implemented, each public shareholder may seek to redeem such shareholder’s public shares for its pro rata portion of the funds available in the trust account, less any income taxes owed on such funds but not yet paid. You will also be able to redeem your public shares in connection with any shareholder vote to approve a proposed business combination, or if the Company has not consummated a business combination by the Extended Date.

			To demand redemption of your public shares, you must ~~check the box on the proxy card provided for that purpose and return the proxy card in accordance with the instructions provided and, at the same time,~~ ensure your bank or broker complies with the requirements identified elsewhere herein.

			In connection with tendering your shares for redemption, you must elect either to physically tender your share certificates to Continental Stock Transfer & Trust Company, the Company’s transfer agent, at Continental Stock Transfer & Trust Company, One State Street Plaza, 30th Floor, New York, New York 10004-1561, Attn: Mark Zimkind, mzimkind@continentalstock.com, at least two business days prior to the special meeting or to deliver your shares to the transfer agent electronically using The Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) System, which election would likely be determined based on the manner in which you hold your shares.


			Certificates that have not been tendered in accordance with these procedures at least two business days prior to the special meeting will not be redeemed for cash. In the event that a public shareholder tenders its shares and decides prior to the special meeting that it does not want to redeem its shares, the shareholder may withdraw the tender. If you delivered your shares for redemption to our transfer agent and decide prior to the special meeting not to redeem your shares, you may request that our transfer agent return the shares (physically or electronically). You may make such request by contacting our transfer agent at the address listed above.

Q.	*What should I do if I receive more than one set of voting materials?*	A.	You may receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards, if your shares are registered in more than one name or are registered in different accounts. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. Please complete, sign, date and return each proxy card and voting instruction card that you receive in order to cast a vote with respect to all of your Longevity shares.

Q.	*Who can help answer my questions?*	A.	If you have questions about the proposals or if you need additional copies of the proxy statement or the enclosed proxy card you should contact:

			Longevity Acquisition Corporation Yongda International Tower No. 2277 Longyang Road, Pudong District Shanghai, People’s Republic of China ~~District~~ Attn: Matthew Chen Telephone: (86) 21-60832028 or: Advantage Proxy, Inc. P.O. Box 13581 Des Moines, WA 98198 Attn: Karen Smith Toll Free: (877) 870-8565 Collect: (206) 870-8565

			You may also obtain additional information about the Company from documents filed with the SEC by following the instructions in the section entitled “Where You Can Find More Information.”

Name and Address of Beneficial Owner⁽¹⁾	Amount and Nature of Beneficial Ownership		Approximate Percentage of Outstanding Ordinary Shares
Whale Management Corporation⁽²⁾⁽³⁾		1,250,000		23.7	%
Matthew Chen⁽²⁾⁽³⁾		1,250,000		23.7	%
Teddy Zheng⁽⁴⁾		—		—
Jun Liu⁽⁴⁾		—		—
Pai Liu⁽⁴⁾		—		—
Yukman Lau⁽⁴⁾		—		—
All directors and officers as a group		1,250,000		23.7	%
Hudson Bay Capital Management LP⁽⁵⁾		478,904		8.8	%
HGC Investment Management Inc.⁽⁶⁾		370,572		6.8	%
Basso Capital Management, L.P.⁽⁷⁾		315,975		6.0	%
Polar Asset Management Partners Inc.⁽⁸⁾		340,000		6.5	%
OxFORD ASSET MANAGEMENT LLP⁽⁹⁾		321,182		6.1	%
Mizuho Financial Group, Inc.⁽¹⁰⁾		376,976		7.2	%
Glazer Capital, LLC⁽¹¹⁾		730,049		13.9	%

Name and Address of Beneficial Owner⁽¹⁾	Amount and Nature of Beneficial Ownership		Approximate Percentage of Outstanding Ordinary Shares
Whale Management Corporation⁽²⁾⁽³⁾		1,250,000		47.6	%
Matthew Chen⁽²⁾⁽³⁾		1,250,000		47.6	%
Teddy Zheng⁽⁴⁾⁽⁵⁾		—		—
Alex Lyamport⁽⁶⁾		—		—
Nicholas H. Adler⁽⁷⁾		—		—
Jerry L Hutter⁽⁸⁾		—		—
Jun Liu⁽⁴⁾⁽⁹⁾		—		—
Pai Liu^(4)(10)		—		—
Yukman Lau^(4)(11)		—		—
All directors and officers as a group		1,250,000		47.6	%

(1)	Unless otherwise noted, the business address of each of the following entities or individuals is c/o Longevity Acquisition Corporation, Yongda International Tower No. 2277 Longyang Road, Pudong District, Shanghai, People’s Republic of ~~China District.~~China.

(2)	Interests shown consist of founder shares and not ordinary shares underlying the private placement units.

(3)	Whale Management Corporation is the record holder of such shares. The shares held by Whale Management Corporation, the Company’s sponsor, are beneficially owned by Matthew Chen, the Company’s Chairman and Chief Executive Officer, who has sole voting and dispositive power over the shares held thereby. Mr. Chen disclaims beneficial ownership over any securities owned by Whale Management Corporation in which he does not have any pecuniary interest. Mr. Chen resigned from his position as the Chief Executive Officer and was appointed as the Chief Financial Officer of the Company on October 22, 2020.

(4)	Does not include any shares held by Whale Management Corporation. This individual is a member of Whale Management Corporation, as described in Footnote 3.

(5)	~~Based on a Schedule 13G/A filed with the SEC on February 4, 2019. Hudson Bay Capital Management LP, a Delaware limited partnership (“Hudson Bay”), serves~~Resigned from his position as the investment manager to Hudson Bay Master Fund Ltd., in whose name the shares reported therein are held. As such, Hudson Bay may be deemed to be the beneficial owner of all shares held by Hudson Bay Master Fund Ltd. Sander Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay. Mr. Gerber disclaims beneficial ownership of these securities. The addressChief Financial Officer of the ~~principal business office of each of the reporting persons is 777 Third Avenue, 30th Floor, New York, NY 10017.~~Company on October 22, 2020.

(6)	~~Based on a Schedule 13G filed with~~Appointed as the ~~SEC on February 13, 2019, on behalf of HGC Investment Management Inc. a company incorporated under the laws of Canada. The principal office~~Chief Executive Officer of the ~~shareholder is 366 Adelaide, Suite 601,~~Company and ~~Toronto, Ontario M5V 1R9, Canada.~~Director of the Board on October 22, 2020.


(7)	~~Based~~Appointed as an Independent Director and the Chairman of the compensation committee of the Board on ~~a Schedule 13G/A filed on February 7,~~October 22, 2020. Such shares are directly beneficially owned by Basso SPAC Fund LLC (“Basso SPAC”), a Delaware limited liability company. Basso Management, LLC (“Basso Management”), a Delaware limited liability company, is the manager of Basso SPAC. Basso Capital Management, L.P. (“BCM”), a Delaware limited partnership, serves as the investment manager of Basso SPAC. Basso GP, LLC (“Basso GP”), a Delaware limited liability company, is the general partner of BCM. Howard I. Fischer is the sole portfolio manager for Basso SPAC, the Chief Executive Officer and a founding managing partner of BCM, and a member of each of Basso Management and Basso GP. Accordingly, each of Basso Management, BCM, Basso GP and Mr. Fischer may be deemed to indirectly beneficially own such shares. The business address of each such persons is 650 Fifth Avenue, New York, New York 10019.

(8)	~~Based~~Appointed as an Independent Director and the Chairman of the audit committee of the Board on ~~a Schedule 13G filed on February 11,~~October 22, 2020. Such shares are directly beneficially owned by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to shares directly held by PMSMF. The business address of each such persons is 401 Bay Street, Suite 1900, PO Box 19, Toronto, Ontario M5H 2Y4, Canada.

(9)	~~Based~~Resigned from his positions as an Independent Director and the Chairman of the compensation committee of the Board on ~~a Schedule 13G filed on February 13,~~October 22, 2020. Such shares are directly beneficially owned by OxFORD Asset Management LLP (“OxFORD”) held for the account of OxAM Quant Fund Limited, a Cayman Islands exempted company (“OxAM”). OxFORD serves as investment adviser to OxAM. The business address of each such persons is OxAM House, 6 George Street, Oxford, United Kingdom, OX1 2BW.

(10)	Based on a Schedule 13G filed on February 14, 2020. Such shares are directly beneficially owned by Mizuho Financial Group, Inc. on behalf of its subsidiaries, Mizuho Bank, Ltd, Mizuho Americas LLC and Mizuho Securities USA LLC. The business addressResigned from his position as the Chairman of the ~~reporting entity is 1–5–5, Otemachi, Chiyoda–ku, Tokyo 100–8176, Japan.~~audit committee of the Board on October 22, 2020.


(11)	~~Based on a Schedule 13G filed on April 9, 2020. Such shares are held by certain funds and managed accounts to which Glazer Capital, LLC serves~~Resigned from his position as ~~investment manager. The business address~~an Independent Director of the ~~reporting entity is 250 West 55th Street, Suite 30A, New York, New York 10019.~~Board on October 22, 2020.

~~Proposal 3 — Adjournment Proposal~~	~~FOR~~ ¨	AGAINST ¨	ABSTAIN ¨
To direct the chairman of the special meeting to adjourn the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the special meeting, there are not sufficient votes to approve the Extension ~~Proposal and the Director~~ Proposal.

	Dated: __________, 2020

	Shareholder’s Signature

	Shareholder’s Signature